PATENT ABSTRACT
Compounds and methods are provided for diagnosing  Trypanosoma cruzi  infection. The disclosed compounds are polypeptides, or antibodies thereto, that contain one or more epitopes of  T. cruzi  antigens. The compounds are useful in a variety of immunoassays for detecting  T. cruzi  infection. The polypeptide compounds are further useful in vaccines and pharmaceutical compositions for inducing protective immunity against Chagas&#39; disease in individuals exposed to  T. cruzi.

PATENT DESCRIPTION
CROSS REFERENCE TO RELATED APPLICATIONS 
     This application is a continuation-in-part of U.S. application Ser. No. 08/834,306, filed Apr. 15, 1997, now U.S. Pat. No. 6,054,135, which claims priority from PCT Application No. PCT/US96/18624, filed Nov. 14, 1996. 
    
    
     TECHNICAL FIELD 
     The present invention relates generally to the diagnosis of  T. cruzi  infection. The invention is more particularly related to the use of one or more  T. cruzi  antigenic peptides, or antibodies thereto, in methods and diagnostic kits to screen individuals and blood supplies for  T. cruzi  infection. The invention is also directed to vaccine compositions for immunizing an individual to prevent Chagas&#39; disease. 
     BACKGROUND OF THE INVENTION 
       
     Protozoan parasites are a serious health threat in many areas of the world.  Trypanosoma cruzi  ( T. cruzi ) is one such parasite that infects millions of individuals, primarily in Central and South America. Infections with this parasite can cause Chagas&#39; disease, which may result in chronic heart disease and a variety of immune system disorders. It is estimated that 18 million people in Latin America are infected with  T. cruzi,  but there is no reliable treatment for the clinical manifestations of infection. No vaccine for the prevention of Chagas&#39; disease is currently available. 
     The most significant route of transmission in areas where the disease is endemic is through contact with an infected triatomid bug. In other areas, however, blood transfusions are the dominant means of transmission. To inhibit the transmission of  T. cruzi  in such regions, it is necessary to develop accurate methods for diagnosing  T. cruzi  infection in individuals and for screening blood supplies. Blood bank screening is particularly important in South America, where 0.1%-62% of samples may be infected and where the parasite is frequently transmitted by blood transfusion. There is also increasing concern that the blood supply in certain U.S. cities may be contaminated with  T. cruzi  parasites. 
     The diagnosis of  T. cruzi  infection has been problematic, since accurate methods for detecting the parasite that are suitable for routine use have been unavailable. During the acute phase of infection, which may last for decades, the infection may remain quiescent and the host may be asymptomatic. As a result, serological tests for  T. cruzi  infection are the most reliable and the most commonly used. 
     Such diagnoses are complicated, however, by the complex life cycle of the parasite and the diverse immune responses of the host. The parasite passes through an epimastigote stage in the insect vector and two main stages in the mammalian host. One host stage is present in blood (the trypomastigote stage) and a second stage is intracellular (the amastigote stage). The multiple stages result in a diversity of antigens presented by the parasite during infection. In addition, immune responses to protozoan infection are complex, involving both humoral and cell-mediated responses to the array of parasite antigens. 
     While detecting antibodies against parasite antigens is the most common and reliable method of diagnosing clinical and subclinical infections, current tests are expensive and difficult. Most serological tests use whole or lysed  T. cruzi  and require positive results on two of three tests, including complement fixation, indirect immunofluorescence, passive agglutination or ELISA, to accurately detect  T. cruzi  infection. The cost and difficulty of such tests has prevented the screening of blood or sera in many endemic areas. 
     Accordingly, there is a need in the art for more specific and sensitive methods of detecting  T. cruzi  infections in blood supplies and individuals. The present invention fulfills these needs and further provides other related advantages. 
     SUMMARY OF THE INVENTION 
     Briefly stated, this invention provides compounds and methods for detecting and protecting against  T. cruzi  infection in individuals and in blood supplies, and for screening for  T. cruzi  infection in biological samples. In one aspect, the present invention provides methods for detecting  T. cruzi  infection in a biological sample, comprising (a) contacting the biological sample with a polypeptide comprising an epitope of a  T. cruzi  antigen having an amino acid sequence encoded by a nucleotide sequence recited in SEQ ID NO: 1-SEQ ID NO:22, or a variant of such an antigen that differs only in conservative substitutions and/or modifications; and (b) detecting in the biological sample the presence of antibodies that bind to the polypeptide, therefrom detecting  T. cruzi  infection in the biological sample. 
     In another aspect of this invention, polypeptides are provided comprising an epitope of a  T. cruzi  antigen having an amino acid sequence encoded by a nucleotide sequence recited in SEQ ID NO: 1-SEQ ID NO:21, or a variant of such an antigen that differs only in conservative substitutions and/or modifications. 
     Within related aspects, DNA sequences encoding the above polypeptides, expression vectors comprising these DNA sequences and host cells transformed or transfected with such expression vectors are also provided. 
     In another aspect, the present invention provides diagnostic kits for detecting  T. cruzi  infection in a biological sample, comprising (a) a polypeptide comprising an epitope of a  T. cruzi  antigen having an amino acid sequence encoded by a nucleotide sequence recited in SEQ ID NO: 1-SEQ ID NO:22, or a variant of such an antigen that differs only in conservative substitutions and/or modifications; and (b) a detection reagent. 
     In yet another aspect of the invention, methods for detecting the presence of  T. cruzi  infection in a biological sample are provided, comprising (a) contacting a biological sample with a monoclonal antibody that binds to an epitope of a  T. cruzi  antigen having an amino acid sequence encoded by a nucleotide sequence recited in SEQ ID NO :1-SEQ ID NO:22, or a variant of such an antigen that differs only in conservative substitutions and/or modifications; and (b) detecting in the biological sample the presence of  T. cruzi  parasites that bind to the monoclonal antibody. 
     Within related aspects, pharmaceutical compositions comprising the above polypeptides and a physiologically acceptable carrier, and vaccines comprising the above polypeptides in combination with an adjuvant, are also provided. 
     The present invention also provides, within other aspects, methods for inducing protective immunity against Chagas&#39; disease in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above. 
     Within other aspects, the present invention provides methods for detecting  T. cruzi  infection in a biological sample, comprising (a) contacting the biological sample with a first polypeptide comprising an epitope of a  T. cruzi  antigen having an amino acid sequence encoded by a nucleotide sequence recited in SEQ ID NO:1-SEQ ID NO:22, or a variant of said antigen that differs only in conservative substitutions and/or modifications; (b) contacting the biological sample with one or more additional polypeptides comprising one or more epitopes of other  T. cruzi  antigens, or a variant thereof that differs only in conservative substitutions and/or modifications; and (c) detecting in the biological sample the presence of antibodies that bind to one or more of said polypeptides, therefrom detecting  T. cruzi  infection in the biological sample. In one embodiment, the additional polypeptide comprises an epitope of TcD, or a variant thereof that differs only in conservative substitutions and/or modifications. In another embodiment, the additional polypeptides comprise an epitope of TcD (or a variant thereof that differs only in conservative substitutions and/or modifications) and an epitope of TcE (or a variant thereof that differs only in conservative substitutions and/or modifications). In yet another embodiment, the additional polypeptides comprise an epitope of TcD (or a variant thereof that differs only in conservative substitutions and/or modifications) and PEP-2 (or a variant thereof that differs only in conservative substitutions and/or modifications). 
     In yet further aspects, the present invention provides combination polypeptides comprising two or more polypeptides, each polypeptide comprising an epitope of a  T. cruzi  antigen having an amino acid sequence encoded by a nucleotide sequence recited in SEQ ID NO:1-SEQ ID NO:22, or a variant thereof that differs only in conservative substitutions and/or modifications. Combination polypeptides comprising at least one epitope of a  T. cruzi  antigen having an amino acid sequence encoded by a nucleotide sequence recited in SEQ ID NO:1-SEQ ID NO:22, or a variant thereof that differs only in conservative substitutions and/or modifications, and at least one epitope selected from the group consisting of TcD epitopes, TcE epitopes, PEP-2 epitopes and variants thereof that differ only in conservative substitutions and/or modifications are also provided. Such combination polypeptides may be prepared either by synthetic means or using recombinant DNA technology. 
     In related aspects, methods are provided for detecting  T. cruzi  infection in a biological sample, comprising (a) contacting the biological sample with at least one of the above combination polypeptides and (b) detecting in the biological sample the presence of antibodies that bind to the combination polypeptide. 
     These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS 
     FIG. 1 is a graph comparing the reactivity of  T. cruzi  lysate and a representative polypeptide of the present invention (rTcc6) in an ELISA assay performed using sera from  T. cruzi -infected (Pos) and uninfected (Neg) individuals. The bars represent ±1 standard deviation. 
     FIG. 2 is a graph presenting a comparison of the reactivity of representative polypeptides of the subject invention in an ELISA assay performed using sera from  T. cruzi -infected (Pos) and uninfected (Neg) individuals. Experiment 1 shows a comparison of rTcc22 and the peptides Tcc22-1 and Tcc22-1+; Experiment 2 shows a comparison of rTcc22, rTcHi12 and the peptides Tcc22-1, Tcc22-1+ and cc22-2.1. The bars represent ±1 standard deviation. 
     FIG. 3 is a graph depicting a comparison of the reactivity of  T. cruzi  lysate and a representative polypeptide (Tcc38) in an ELISA assay performed using sera from  T. cruzi -infected (Pos) and uninfected (Neg) individuals, as well as using sera from individuals with visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), tuberculosis (TB) and malaria. The bars represent ±1 standard deviation. 
     FIG. 4 is a graph presenting a comparison of the reactivity of  T. cruzi  lysate and several polypeptides of the present invention, representing different reading frames of the TcLo1 and TcHi10 antigens, in an ELISA assay performed using sera from  T. cruzi -infected (Pos) and uninfected (Neg) individuals. The bars represent +1 standard deviation. 
     FIG. 5 is a graph comparing the reactivity of  T. cruzi  lysate and a representative polypeptide (TccLo1.2) in an ELISA assay performed using sera from  T. cruzi -infected (Pos) and uninfected (Neg) individuals, as well as sera from individuals with visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), malaria and tuberculosis (TB). 
     FIG. 6 is a graph depicting the ELISA reactivity of a series of polypeptide combinations with  T. cruzi  positive and negative sera. 
     FIG. 7 is a graph presenting the ELISA reactivity of a series of TcE polypeptide variants with  T. cruzi  positive and negative sera. 
     FIG. 8 is a graph comparing the ELISA reactivity of two dipeptides, a tripeptide and a tetrapeptide of the present invention with  T. cruzi  positive and negative sera. 
     FIG. 9 is a graph presenting the ELISA reactivity of a representative polypeptide of the present invention (TcHi29) and of TcE with sera from normal individuals,  T. cruzi  patients, and patients with other diseases. 
     FIG. 10 is a graph comparing the ELISA reactivity of two representative dipeptide mixtures with  T. cruzi  positive and negative sera, one mixture including a TcE epitope and the other including a TcHi29 epitope of the present invention. 
     FIG. 11 is a graph comparing the ELISA reactivity of the recombinant fusion polypeptide TcF with sera from  T. cruzi  patients and from normal donors with the reactivity of the synthetic branched tetrapeptide 2/D/E/Lo1.2. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     As noted above, the present invention is generally directed to compounds and methods for detecting and protecting against  T. cruzi  infection in individuals and in blood supplies. The compounds of this invention generally comprise one or more epitopes of  T. cruzi  antigens. In particular, polypeptides comprising an epitope of a  T. cruzi  antigen having an amino acid sequence encoded by a nucleotide sequence recited in SEQ ID NO:1-SEQ ID NO:22are preferred. As used herein, the term “polypeptide” encompasses amino acid chains of any length, including full length (i.e., native) antigens. Thus, a polypeptide comprising an epitope may consist entirely of the epitope or may contain additional sequences. The additional sequences may be derived from the native antigen or may be heterologous, and such sequences may (but need not) be antigenic. A protein “having” a particular amino acid sequence is a protein that contains, within its full length sequence, the recited sequence. Such a protein may, or may not, contain additional amino acid sequence. The use of one or more epitopes from additional  T. cruzi  proteins, prior to or in combination with one or more epitopes of sequences recited herein, to enhance the sensitivity and specificity of the diagnosis, is also contemplated. 
     An “epitope,” as used herein, is a portion of a  T. cruzi  antigen that reacts with sera from  T. cruzi -infected individuals (i.e., an epitope is specifically bound by one or more antibodies within such sera). Epitopes of the antigens described in the present application may generally be identified using methods known to those of ordinary skill in the art, such as those summarized in Paul, Fundamental Immunology, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. For example, a polypeptide derived from a native  T. cruzi  antigen may be screened for the ability to react with pooled sera obtained from  T. cruzi -infected patients. Suitable assays for evaluating reactivity with  T. cruzi -infected sera, such as an enzyme linked immunosorbent assay (ELISA), are described in more detail below, and in Harlow and Lane,  Antibodies: A Laboratory Manual,  Cold Spring Harbor Laboratory, 1988. An epitope of a polypeptide is a portion that reacts with such antisera at a level that is substantially similar to the reactivity of the full length polypeptide. In other words, an epitope may generate at least about 80%, and preferably at least about 100%, of the response generated by the full length polypeptide in an antibody binding assay (e.g., an ELISA). 
     The compounds and methods of this invention also encompass variants of the above polypeptides. As used herein, a “variant” is a polypeptide that differs from the recited polypeptide only in conservative substitutions or modifications, such that it retains the antigenic properties of the recited polypeptide. A “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. Variants may also, or alternatively, contain other conservative modifications, including the deletion or addition of amino acids that have minimal influence on the antigenic properties, secondary structure and hydropathic nature of the polypeptide. For example, the polypeptide may be conjugated to a linker or other sequence for ease of synthesis or to enhance binding of the polypeptide to a solid support. 
     In a related aspect, combination polypeptides comprising epitopes of multiple  T. cruzi  antigens are disclosed. A “combination polypeptide” is a polypeptide in which epitopes of different  T. cruzi  antigens, or variants thereof, are joined, for example through a peptide linkage, into a single amino acid chain. The amino acid chain thus formed may be either linear or branched. The epitopes may be joined directly (i.e., with no intervening amino acids) or may be joined by way of a linker sequence (e.g., Gly-Cys-Gly) that does not significantly alter the antigenic properties of the epitopes. The peptide epitopes may also be linked through non-peptide linkages, such as hetero- or homo-bifunctional agents that chemically or photochemically couple between specific functional groups on the peptide epitopes such as through amino, carboxyl, or sulfhydryl groups. Bifunctional agents which may be usefully employed in the combination polypeptides of the present invention are well known to those of skill in the art. Epitopes may also be linked by means of a complementary ligand/anti-ligand pair, such as avidin/biotin, with one or more epitopes being linked to a first member of the ligand/anti-ligand pair and then being bound to the complementary member of the ligand/anti-ligand pair either in solution or in solid phase. A combination polypeptide may contain multiple epitopes of polypeptides as described herein and/or may contain epitopes of one or more other  T. cruzi  antigens, such as TcD, TcE or PEP-2, linked to an epitope described herein. 
     In general,  T. cruzi  antigens, and DNA sequences encoding such antigens, may be prepared using any of a variety of procedures. For example, a  T. cruzi  cDNA or genomic DNA expression library may be screened with pools of sera from  T. cruzi -infected individuals. Such screens may generally be performed using techniques well known to those of ordinary skill in the art, such as those described in Sambrook et al.,  Molecular Cloning: A Laboratory Manual,  Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989. Briefly, the bacteriophage library may be plated and transferred to filters. The filters may then be incubated with serum and a detection reagent. In the context of this invention, a “detection reagent” is any compound capable of binding to the antibody-antigen complex, which may then be detected by any of a variety of means known to those of ordinary skill in the art. Typical detection reagents for screening purposes contain a “binding agent,” such as Protein A, Protein G, IgG or a lectin, coupled to a reporter group. Preferred reporter groups include, but are not limited to, enzymes, substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. More preferably, the reporter group is horseradish peroxidase, which may be detected by incubation with a substrate such as tetramethylbenzidine or 2,2′-azino-di-3-ethylbenzthiazoline sulfonic acid. Plaques containing cDNAs that express a protein that binds to an antibody in the serum may be isolated and purified by techniques known to those of ordinary skill in the art. Appropriate methods may be found, for example, in Sambrook et al.,  Molecular Cloning: A Laboratory Manual,  Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989. 
     DNA molecules having the nucleotide sequences recited in SEQ ID NO:1-SEQ ID NO:18 may be isolated by screening a  T. cruzi  genomic expression library with pools of sera from  T. cruzi -infected individuals, as described above. More specifically, DNA molecules having the nucleotide sequences recited in SEQ ID NO: 1-SEQ ID NO:16 may be isolated by screening the library with a pool of sera that displays serological reactivity (in an ELISA or Western assay) with parasite lysate and/or one or both of the  T. cruzi  antigens TcD and TcE, described in U.S. Pat. No. 5,304,371 and U.S. Ser. No. 08/403,379, filed Mar. 14, 1995. A subsequent screen is then performed with patient sera lacking detectable anti-TcD antibody. A DNA molecule having the nucleotide sequences recited in SEQ ID NO:17 (5′ end) and SEQ ID NO:18 (3′ end) may be isolated by screening the genomic expression library with a pool of sera that displays lower serological reactivity (i.e., detects a signal less than 3 standard deviations over background reactivity in an ELISA or Western assay) with lysate, TcD and TcE, followed by a subsequent screen with patient sera lacking detectable anti-TcD antibody. 
     DNA molecules having the sequences recited in SEQ ID NO:19-SEQ ID NO:22 may be obtained by screening an unamplified  T. cruzi  cDNA expression library with sera (both higher and lower serological reactivity) from  T. cruzi -infected individuals, as described above. 
     Alternatively, DNA molecules having the sequences recited in SEQ ID NO:1-SEQ ID NO:22 may be amplified from  T. cruzi  genomic DNA or cDNA via polymerase chain reaction. For this approach, sequence-specific primers may be designed based on the sequences provided in SEQ ID NO:1-SEQ ID NO:22, and may be purchased or synthesized. An amplified portion of the DNA sequences may then be used to isolate the full length genomic or cDNA clones using well known techniques, such as those described in Sambrook et al.,  Molecular Cloning: A Laboratory Manual,  Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y. (1989). 
     Epitopes of antigens having amino acid sequences encoded by the above DNA sequences may generally be identified by generating polypeptides containing portions of the native antigen and evaluating the reactivity of the polypeptides with sera from  T. cruzi -infected individuals, as described above. In many instances, peptides comprising one or more repeat sequences found in the native antigen contain an epitope. Such repeat sequences may be identified based on inspection of the above nucleotide sequences. Representative repeat sequences for antigens encoded by the above DNA sequences are provided in SEQ ID NO:23-SEQ ID NO:36 and SEQ ID NO:47-SEQ ID NO:49. More specifically, repeat sequences for the sequence recited in SEQ ID NO:3 are provided in SEQ ID NO:23 (Frame 1), SEQ ID NO:24 (Frame 2) and SEQ ID NO:25 (Frame 3). Repeat sequences for the sequence recited in SEQ ID NO:4 are provided in SEQ ID NO:26 (Frame 1) and SEQ ID NO:27 (Frame 3) and repeat sequences for SEQ ID NO:9 are provided in SEQ ID NO:47 (Frame 1), SEQ ID NO:48 (Frame 2) and SEQ ID NO:49 (Frame 3). For SEQ ID NO:12, repeat sequences are provided in SEQ ID NO:28 (Frame 1), SEQ ID NO:29 (Frame 2) and SEQ ID NO:30 (Frame 3). SEQ ID NO:31 recites a repeat sequence for SEQ ID NO:15. For SEQ ID NO:16, repeat sequences are provided in SEQ ID NO:32 (Frame 2) and SEQ ID NO:33 (Frame 3). Finally, repeat sequences for SEQ ID NO:18 are provided in SEQ ID NO:34 (Frame 1), SEQ ID NO:35 (Frame 2) and SEQ ID NO:36 (Frame 3). 
     The polypeptides described herein may be generated using techniques well known to those of ordinary skill in the art. Polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, can be synthesized using, for example, the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield,  J. Am. Chem. Soc.  85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied Biosystems Division, Foster City, Calif. Thus, for example, polypeptides comprising the above repeat sequences or portions thereof, may be synthesized by this method. Similarly, epitopes of other native antigens, or variants thereof, may be prepared using an automated synthesizer. 
     Alternatively, the polypeptides of this invention may be prepared by expression of recombinant DNA encoding the polypeptide in cultured host cells. Preferably, the host cells are  E. coli,  yeast, an insect cell line (such as Spodoptera or Trichoplusia) or a mammalian cell line, including (but not limited to) CHO, COS and NS-1. The DNA sequences expressed in this manner may encode naturally occurring proteins, such as full length antigens having the amino acid sequences encoded by the DNA sequences of SEQ ID NO:1-SEQ ID NO:22, portions of naturally occurring proteins, or variants of such proteins. Representative polypeptides encoded by such DNA sequences are provided in SEQ ID NO:37-SEQ ID NO:46, SEQ ID NO:52, and SEQ ID NO:65. 
     Expressed polypeptides of this invention are generally isolated in substantially pure form. Preferably, the polypeptides are isolated to a purity of at least 80% by weight, more preferably, to a purity of at least 95% by weight, and most preferably to a purity of at least 99% by weight. In general, such purification may be achieved using, for example, the standard techniques of ammonium sulfate fractionation, SDS-PAGE electrophoresis, and affinity chromatography. 
     In another aspect of this invention, methods for detecting  T. cruzi  infection in individuals and blood supplies are disclosed. In one embodiment,  T. cruzi  infection may be detected in any biological sample that contains antibodies. Preferably, the sample is blood, serum, plasma, saliva, cerebrospinal fluid or urine. More preferably, the sample is a blood or serum sample obtained from a patient or a blood supply. Briefly,  T. cruzi  infection may be detected using any one or more of the polypeptides described above, or variants thereof, to determine the presence or absence of antibodies to the polypeptide or polypeptides in the sample, relative to a predetermined cut-off value. 
     There are a variety of assay formats known to those of ordinary skill in the art for using purified antigen to detect antibodies in a sample. See, e.g., Harlow and Lane,  Antibodies: A Laboratory Manual,  Cold Spring Harbor Laboratory, 1988. In a preferred embodiment, the assay involves the use of polypeptide immobilized on a solid support to bind to and remove the antibody from the sample. The bound antibody may then be detected using a detection reagent that binds to the antibody/peptide complex and contains a detectable reporter group. Suitable detection reagents include antibodies that bind to the antibody/polypeptide complex and free polypeptide labeled with a reporter group (e.g., in a semi-competitive assay). Alternatively, a competitive assay may be utilized, in which an antibody that binds to the polypeptide is labeled with a reporter group and allowed to bind to the immobilized antigen after incubation of the antigen with the sample. The extent to which components of the sample inhibit the binding of the labeled antibody to the polypeptide is indicative of the reactivity of the sample with the immobilized polypeptide. 
     The solid support may be any solid material known to those of ordinary skill in the art to which the antigen may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Pat. No. 5,359,681. 
     The polypeptide may be bound to the solid support using a variety of techniques known to those in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term “bound” refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Binding by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the polypeptide, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of polypeptide ranging from about 10 ng to about 1 μg, and preferably about 100 ng, is sufficient to bind an adequate amount of antigen. Nitrocellulose will bind approximately 100 μg of protein per cm 3 . 
     Covalent attachment of polypeptide to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the polypeptide. For example, the polypeptide may be bound to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the polypeptide (see, e.g., Pierce Immunotechnology Catalog and Handbook (1991) at A12-A13). 
     In certain embodiments, the assay is an enzyme linked immunosorbent assay (ELISA). This assay may be performed by first contacting a polypeptide antigen that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that antibodies to the polypeptide within the sample are allowed to bind to the immobilized polypeptide. Unbound sample is then removed from the immobilized polypeptide and a detection reagent capable of binding to the immobilized antibody-polypeptide complex is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific detection reagent. 
     Once the polypeptide is immobilized on the support, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20 TM (Sigma Chemical Co., St. Louis, Mo.). The immobilized polypeptide is then incubated with the sample, and antibody (if present in the sample) is allowed to bind to the antigen. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (i.e., incubation time) is that period of time that is sufficient to permit detect the presence of  T. cruzi  antibody within a  T. cruzi -infected sample. Preferably, the contact time is sufficient to achieve a level of binding that is at least 95% of that achieved at equilibrium between bound and unbound antibody. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient. 
     Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. Detection reagent may then be added to the solid support. An appropriate detection reagent is any compound that binds to the immobilized antibody-polypeptide complex and that can be detected by any of a variety of means known to those in the art. Preferably, the detection reagent contains a binding agent (such as, for example, Protein A, Protein G, immunoglobulin, lectin or free antigen) conjugated to a reporter group. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of binding agent to reporter group may be achieved using standard methods known to those of ordinary skill in the art. Common binding agents may also be purchased conjugated to a variety of reporter groups from many sources (e.g., Zymed Laboratories, San Francisco, Calif. and Pierce, Rockford, Ill.). 
     The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound antibody. An appropriate amount of time may generally be determined from the manufacturer&#39;s instructions or by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products. 
     To determine the presence or absence of  T. cruzi  antibodies in the sample, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. This cut-off value is preferably the average mean signal obtained when the immobilized antigen is incubated with samples from an uninfected patient. In general, a sample generating a signal that is three standard deviations above the mean is considered positive for  T. cruzi  antibodies and  T. cruzi  infection. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al.,  Clinical Epidemiology: A Basic Science for Clinical Medicine,  p. 106-7 (Little Brown and Co., 1985). Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (ie., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for  T. cruzi  infection. 
     In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the antigen is immobilized on a membrane such as nitrocellulose. In the flow-through test, antibodies within the sample bind to the immobilized polypeptide as the sample passes through the membrane. A detection reagent (e.g., protein A-colloidal gold) then binds to the antibody-polypeptide complex as the solution containing the detection reagent flows through the membrane. The detection of bound detection reagent may then be performed as described above. In the strip test format, one end of the membrane to which polypeptide is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing detection reagent and to the area of immobilized polypeptide. Concentration of detection reagent at the polypeptide indicates the presence of  T. cruzi  antibodies in the sample. Such tests can typically be performed with a very small amount (e.g., one drop) of patient serum or blood. 
     The assays discussed above may be performed using one or more of the polypeptides described herein. Alternatively, the sensitivity may be improved by using epitopes of one or more additional  T. cruzi  antigens in combination with the above polypeptide(s). In particular, epitopes of TcD (disclosed, for example, in U.S. Pat. No. 5,304,371), PEP-2 and/or TcE (both of which are disclosed, for example, in U.S. Ser. No. 08/403,379, filed Mar. 14, 1995) may be used in conjunction with the above polypeptide(s). The PEP-2 antigenic epitope is also discussed in Peralta et al.,  J. Clin. Microbiol.  32:971-74, 1994. The sequence of TcD is provided in SEQ ID NO:50, the sequence of TcE is provided in SEQ ID NO:51. The TcD antigenic epitope preferably has the amino acid sequence Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser (SEQ ID NO:53)or the amino acid sequence Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro (SEQ ID NO:54). The TcE epitope preferably has the amino acid sequence Lys Ala Ala Ile Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Thr Ala Pro Ala (SEQ ID NO: 55) or the amino acid sequence Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala (SEQ ID NO:56), and the PEP2 epitope preferably has the amino acid sequence Gly Asp Lys Pro Ser Pro Phe Gly Gln Ala Ala Ala Gly Asp Lys Pro Ser Pro Phe Gly Gln Ala (SEQ ID NO:57). 
     Additional epitopes may be present within the same polypeptide (i.e., in a combination polypeptide) or may be included in separate polypeptides. Combination polypeptides may be prepared either synthetically, as described below in Example 2, or using recombinant DNA technology as detailed below in Example 7. Preferably, the polypeptides are immobilized by adsorption on a solid support such as a well of a microtiter plate or a membrane, as described above, such that a roughly similar amount of each polypeptide contacts the support, and such that the total amount of polypeptide in contact with the support ranges from about 1 ng to about 10 μg. The remainder of the steps may generally be performed as described above. 
     The polypeptides described above may also be used following diagnosis using one or more of the epitopes from TcD, TcE and/or PEP2. In this embodiment, the polypeptides of the present invention are used to confirm a diagnosis of  T. cruzi  infection based on a screen with TcD, TcE and/or PEP2. Diagnosis of  T. cruzi  infection using epitopes from TcD, TcE and/or PEP2 is described in U.S. Ser. No. 08/403,379, filed Mar. 14, 1995. 
     In yet another aspect of this invention, methods are provided for detecting  T. cruzi  in a biological sample using monospecific antibodies (which may be polyclonal or monoclonal) to one or more epitopes, as described above. Antibodies to purified or synthesized polypeptides may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane,  Antibodies: A Laboratory Manual,  Cold Spring Harbor Laboratory, 1988. In one such technique, an immunogen comprising the antigenic polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep and goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support. 
     Monoclonal antibodies specific for the antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein,  Eur. J Immunol.  6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (ie., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about I to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred. 
     Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. 
     Monospecific antibodies to epitopes of one or more of the polypeptides described herein may be used to detect  T. cruzi  infection in a biological sample using any of a variety of immunoassays, which may be direct or competitive. Suitable biological samples for use in this aspect of the present invention are as described above. Briefly, in one direct assay format, a monospecific antibody may be immobilized on a solid support (as described above) and contacted with the sample to be tested. After removal of the unbound sample, a second monospecific antibody, which has been labeled with a reporter group, may be added and used to detect bound antigen. In an exemplary competitive assay, the sample may be combined with the monoclonal or polyclonal antibody, which has been labeled with a suitable reporter group. The mixture of sample and antibody may then be combined with polypeptide antigen immobilized on a suitable solid support. Antibody that has not bound to an antigen in the sample is allowed to bind to the immobilized antigen, and the remainder of the sample and antibody is removed. The level of antibody bound to the solid support is inversely related to the level of antigen in the sample. Thus, a lower level of antibody bound to the solid support indicates the presence of  T. cruzi  in the sample. To determine the presence or absence of  T. cruzi  infection, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. Such cut-off values may generally be determined as described above. Any of the reporter groups discussed above in the context of ELISAs may be used to label the monospecific antibodies, and binding may be detected by any of a variety of techniques appropriate for the reporter group employed. Other formats for using monospecific antibodies to detect  T. cruzi  in a sample will be apparent to those of ordinary skill in the art, and the above formats is provided solely for exemplary purposes. 
     In another aspect of this invention, vaccines and pharmaceutical compositions are provided for the prevention of  T. cruzi  infection, and complications thereof, in a mammal. The pharmaceutical compositions generally comprise one or more polypeptides, containing one or more epitopes of  T. cruzi  proteins, and a physiologically acceptable carrier. The vaccines comprise one or more of the above polypeptides and an adjuvant, for enhancement of the immune response. 
     Routes and frequency of administration and polypeptide doses will vary from individual to individual and may parallel those currently being used in immunization against other protozoan infections. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 4 doses may be administered for a 2-6 week period. Preferably, two doses are administered, with the second dose 2-4 weeks later than the first. A suitable dose is an amount of polypeptide that is effective to raise antibodies in a treated mammal that are sufficient to protect the mammal from  T. cruzi  infection for a period of time. In general, the amount of polypeptide present in a dose ranges from about 1 μg to about 100 mg per kg of host, typically from about 10 μg to about 1 mg, and preferably from about 100 μg to about 1 μg. Suitable dose sizes will vary with the size of the animal, but will typically range from about 0.01 mL to about 5 mL for 10-60 kg animal. 
     While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic galactide) may also be employed as carriers for the pharmaceutical compositions of this invention. 
     Any of a variety of adjuvants may be employed in the vaccines of this invention to nonspecifically enhance the immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a nonspecific stimulator of immune response, such as lipid A,  Bordella pertussis  or  Mycobacterium tuberculosis.  Such adjuvants are commercially available as, for example, Freund&#39;s Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.). 
     The following Examples are offered by way of illustration and not by way of limitation. 
     EXAMPLES 
     Example 1 
     Preparation of DNA Encoding  T. cruzi  Antigens 
     This Example illustrates the preparation of genomic and cDNA molecules encoding  T. cruzi  Antigens. 
     A. Preparation of Genomic Clones 
     A genomic expression library was constructed from randomly sheared  T. cruzi  genomic DNA (Tulahuen C2 strain) using the Lambda ZAP expression system (Stratagene, La Jolla, Calif.) according to the manufacturer&#39;s instructions. In one screen, the library was screened with a pool of sera from five patients that displayed high reactivity with parasite lysate and/or one or both of the  T. cruzi  antigens TcD and TcE, described in U.S. Pat. No. 5,304,371 and U.S. Ser. No. 08/403,379, filed Mar. 14, 1995. Each of the five patients&#39; sera was determined to be reactive based on Western and ELISA assays with whole lysate and/or TcD or TcE. Anti- E. coli  reactivity was removed from the serum prior to screening by adsorption. 50,000 pfu of the unamplified library was screened with the serum pool and plaques expressing proteins that reacted with the serum were detected using protein A-horseradish peroxidase (with the ABTS substrate). A subsequent screen was then performed with a pool of sera from three patients lacking detectable anti-TcD antibody in Western and ELISA assays using recombinant TcD. 
     A similar screen was performed using a pool of sera that displayed low reactivity with lysate, TcD and TcE (ie., detected a signal less than 3 standard deviations over background reactivity in an ELISA or Western assay), followed by a subsequent screen with patient sera lacking detectable anti-TcD antibody, as described above. 
     Twenty-eight clones that expressed proteins which reacted with both pools of sera in at least one of the above screens were then isolated. Excision of the pBSK(−) phagemid (Stratagene, Inc., La Jolla, Calif.) was carried out according to the manufacturer&#39;s protocol. Overlapping clones were generated by exonuclease III digestion and single-stranded templates were isolated after infection with VCSM 13 helper phage. The DNA was sequenced by the dideoxy chain termination method or by the Taq di-terminator system, using an Applied Biosystem automated sequencer, Model 373A. 
     Of the 28 clones, five had been reported previously, two were identical, and eight contained identical peptide sequences represented by a degenerate 42 base pair repeat. SEQ ID NO:16 shows the prototype clone containing the 42 base pair repeat sequence. Accordingly, 14 novel DNA sequences encoding  T. cruzi  antigens were prepared using the above screen with the reactive pool of sera (shown in SEQ ID NO:1-SEQ ID NO:16, where SEQ ID NO:4 and SEQ ID NO:5 represent the 5′ and 3′ ends, respectively, of a single clone, SEQ ID NO:9 and SEQ ID NO:10 represent the 5′ and 3′ ends, respectively, of a single clone. One novel sequence was obtained with the screen employing the sera with low reactivity (shown in SEQ ID NO:17 (5′ end) and SEQ ID NO:18 (3′ end)). 
     B. Preparation of cDNA Clones 
     Poly A+ RNA was purified from the intracellular amastigote stage of  T. cruzi  (Tulahuen C2 strain). The RNA was reverse transcribed and used in the construction of a unidirectional cDNA expression library in the Lambda UniZap expression vector (Stratagene, La Jolla, Calif.) according to the manufacturer&#39;s instructions. 50,000 pfu of the unamplified library was screened with a serum pool containing patient sera that displayed both high and low serological reactivity, followed by a subsequent screen with patient sera lacking detectable anti-TcD antibody, as described above. A total of 32 clones were isolated from this screen. Twenty-five of these clones were proteins of the translational apparatus that have been previously identified as highly immunogenic, and all were different from the clones identified by screening the genomic expression library. The remaining seven are represented by the sequences provided in SEQ ID NO:19-SEQ ID NO:22. The sequence recited in SEQ ID NO:22 is that of  T. cruzi  ubiquitin. 
     Example 2 
     Synthesis of Synthetic Polypeptides 
     This Example illustrates the synthesis of polypeptides having sequences derived from  T. cruzi  antigens described herein. 
     Polypeptides may be synthesized on a Millipore 9050 peptide synthesizer using FMOC chemistry with HBTU (O-benzotriazole-N,N,N′,N′-tetramethyuronium hexafluorophosphate) activation. A gly-cys-gly sequence may be attached to the amino or carboxyl terminus of the peptide to provide a method of conjugation or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanediol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of 0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1%TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides are characterized using electrospray mass spectrometry and by amino acid analysis. 
     This procedure was used to synthesize peptides such as Tcc22-1,Tcc22-1+, Tcc22-2.1 (contained within SEQ ID NO:41), TcLo1.1,1.2 and 1.3 (contained within SEQ ID NOs 34, 35 and 36) and TcHi10.1 and 10.3 (SEQ ID NOs 26 and 27) which have the following sequences: 
     
       
         
               
               
               
             
           
               
                 Tcc22-1 
                                                  VRASNCRKKACGHCSNLRMKKK 
                   
               
               
                   
               
               
                 Tcc22-1+ 
                             EALAKKYNWEKKVCRRCYARLPVRASNCRKKACGHCSNLRMKKK 
               
               
                   
               
               
                 Tcc22-2.1 
                 VLRLRGGVMEPTLEALAKKYNWEKKVCRRCYARL 
               
               
                   
               
               
                 TcLo1.1 
                 GYVRGRKQRWQLHACGYVRGRKQRRQLHACGYVRGRKQRWQLHAF 
               
               
                   
               
               
                 TcLo1.2 
                 GTSEEGSRGGSSMPSGTSEBGSRGGSSMPA 
               
               
                   
               
               
                 TcLo1.3 
                 VRPRKEAEVAAPCLRVRPRKEAEEAAPCLR 
               
               
                   
               
               
                 TcHi10.1 
                 SVPGKRLRNSHGKSLRNVHGKRPKNEHGKRLRSVPNERLR 
               
               
                   
               
               
                 TcHi10.3 
                 EAEELARQESEERARQEAEERAWQEAEERAQREAEERAQR 
               
             
          
         
       
     
     Example 3 
     Serological Reactivity of  T. cruzi  Recombinant Antigens 
     This example illustrates the diagnostic properties of several recombinant antigens found to be serologically active. This includes studies of reactivity with  T. cruzi  positive and negative sera as well as cross reactivity studies with sera from patients with other diseases. 
     Assays were performed in 96 well plates (Corning Easiwash, Corning, N.Y.). Wells were coated in 50 μl of carbonate coating buffer pH 9.6. For  T. cruzi  lysate, 100 ng/well was used, and for each of the recombinant antigens 200 ng/well was used. The wells were coated overnight at 4° C. (or 2 hours at 37° C.). The plate contents were then removed and wells were blocked for 2 hours with 200 μl of PBS/1%BSA. After the blocking step, the wells were washed five times with PBS/0.1% Tween 20™. 50 μl of sera (either positive or negative for  T. cruzi  infection), diluted 1:50 in PBS/0.1% Tween 20/0.1%BSA was then added to each well and incubated for 30 minutes at room temperature. The plates were then washed again five times with PBS/0.1% Tween 20™. 
     The enzyme conjugate (horse radish peroxidase-Protein A, Zymed, San Francisco, Calif.) was then diluted 1:20,000 in PBS/0.1% Tween 20™/0.1%BSA, and 50 μl of the diluted conjugate was added to each well and incubated for 30 minutes at room temperature. Following incubation the wells were again washed five times with PBS/0.1% Tween 20™. 100 μl of the peroxidase substrate, tetramethylbenzidine (Kirkegaard and Perry Laboratories, Gaithersburg, Md.) was added, undiluted, to each of the wells and incubated for 15 minutes. The reaction was stopped by the addition of 100 μl of 1N H 2 SO 4  to each well, and the plates were read at 450 nm. 
     FIG. 1 shows the reactivity of the recombinant rTcc6 (SEQ ID NO:39) as compared to that of  T. cruzi  lysate. Based on a cutoff of the mean of the negatives plus 3 standard deviations, 49 out of 50 serum samples were positive with lysate, and 34 out of 50 were positive with rTcc6. In a similar study (shown in FIG.  2 ), the recombinant rTcc22 (SEQ ID NO:41) was found to have a sensitivity of 79.2% (38 out of 48 serum samples were positive). Comparative studies of the recombinant rTcc38 (SEQ ID NO:38) with  T. cruzi  lysate using similar criteria showed that 24/39 were positive compared with 39/39 for lysate (FIG.  3 ). Tcc38 when tested with potentially cross reacting sera showed improved specificity over  T. cruzi  lysate. 
     The recombinant TcHi12 (SEQ ID NO:37) was also found to be immunoreactive (FIG. 2) having a sensitivity of 62.5% (15/24). 
     Example 4 
     Serological Reactivity of  T. cruzi  Synthetic Peptide Antigens 
     This example illustrates the diagnostic properties of several of the peptides described in Example 2. These peptides were tested for reactivity with  T. cruzi  positive and negative sera and, in some cases, for cross reactivity with sera from patients with other, potentially cross reactive, diseases. 
     The first group of peptides included different reading frames to determine the most reactive repeat sequence. The peptides tested were TcLol.1 (contained within SEQ ID NO:34), TcLo1.2 (contained within SEQ ID NO:35) and TcLo1.3 (contained within SEQ ID NO:36), representing reading frames 1, 2 and 3 of the DNA sequence provided in SEQ ID NO:18, and TcHi10.1 (SEQ ID NO:26) and TcHi10.3 (SEQ ID NO:27) which represent two of the reading frames for the TcHi10 sequence (shown in SEQ ID NO:5). The data is shown in FIG.  4 . In the case of the TcLo frames, both the TcLo1.1 and 1.2 peptides were strongly reactive but the TcLo1.2 was superior in signal to noise when tested on sera from  T. cruzi  positive and negative individuals. TcLo1.3 had lower signal but also low background. In this study lysate detected 24/24 positives, TcLo1.1 detected 21/24, TcLo1.2 detected 23/24 and TcLo1.3 detected 15/24. In the same study, the two frames TcHi10.1 and 10.3 detected 19/24 and 14/24 positives respectively, but with lower signal than for TcLo1. Cross reactivity studies with these different reading frames demonstrate that TcLo1.2 has minimal cross reactivity with the sera tested (FIG. 5) as compared to  T. cruzi  lysate. 
     As discussed in Example 2, overlapping peptides were also synthesized for rTcc22 to determine the active epitope. The peptides Tcc22- 1, 1+ and 2 were tested with  T. cruzi  positive and negative sera. The results are shown in FIG.  2 . The Tcc22-1+ and Tcc22-2.1 peptides were more reactive than the Tcc22-1 peptide. In the first experiment, Tcc22-1 and Tcc22-1+ detected 29/48 and 36/48 positives as compared to the recombinant Tcc22 which detected 38/48 positives. In a subsequent experiment, Tcc22-2.1 was also shown to be reactive but with less signal than Tcc22-1+ at the same plate coating level. 
     A polypeptide having the TcHi15 frame 3 repeat sequence (SEQ ID NO:49) was also synthesized and tested in an ELISA assay using a coating level of 200 ng/well. A total of 48  T. cruzi  positive sera and 26 negative sera were tested in order to determine the reactivity of this peptide sequence. In this study, the peptide had a sensitivity of 68.75% (detecting 33 out of 48 positives) and a specificity of 92.3% (24 out of 36 negatives), indicating that this polypeptide has potential significance in detecting  T. cruzi  infections. The results of this assay are presented in Table 1, below. 
     
       
         
               
             
               
               
               
               
               
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 1 
               
             
             
               
                   
               
               
                 Reactivity of TcHi15 Frame 3 Polypeptide with  T. cruzi - 
               
               
                 Positive and Negative Sera 
               
             
          
           
               
                   
                 
                   T. cruzi 
                 
                   
                   
                 
                   T. cruzi 
                 
                   
               
               
                 Sample ID 
                 Status 
                 OD 450 
                 Sample ID 
                 Status 
                 OD 450 
               
               
                   
               
             
          
           
               
                 Tc011095-1  
                 Positive 
                 0.696 
                 DL4-0106 
                 Negative 
                 0.167 
               
               
                 Tc011095-2  
                 Positive 
                 0.699 
                 DL4-0112 
                 Negative 
                 0.05 
               
               
                 Tc011095-3  
                 Positive 
                 1.991 
                 DL4-0127 
                 Negative 
                 0.240 
               
               
                 Tc011095-4  
                 Positive 
                 3 
                 DL4-0140 
                 Negative 
                 0.008 
               
               
                 Tc011095-5  
                 Positive 
                 0.098 
                 DL4-0145 
                 Negative 
                 0.107 
               
               
                 Tc011095-6  
                 Positive 
                 0.238 
                 DL4-0161 
                 Negative 
                 0.119 
               
               
                 Tc011095-7  
                 Positive 
                 0.115 
                 DL4-0162 
                 Negative 
                 1.187 
               
               
                 Tc011095-8  
                 Positive 
                 0.156 
                 DL4-0166 
                 Negative 
                 0.210 
               
               
                 Tc011095-9  
                 Positive 
                 0.757 
                 DL4-0167 
                 Negative 
                 0.131 
               
               
                 Tc011095-10 
                 Positive 
                 1.147 
                 DL4-0172 
                 Negative 
                 0.073 
               
               
                 Tc011095-11 
                 Positive 
                 0.264 
                 DL4-0175 
                 Negative 
                 0.117 
               
               
                 Tc011095-12 
                 Positive 
                 1.7 
                 DL4-0176 
                 Negative 
                 0.815 
               
               
                 Tc011095-13 
                 Positive 
                 1.293 
                 AT4-0013 
                 Negative 
                 0.100 
               
               
                 Tc011095-14 
                 Positive 
                 0.242 
                 AT4-0041 
                 Negative 
                 0.107 
               
               
                 Tc011095-15 
                 Positive 
                 0.636 
                 AT4-0062 
                 Negative 
                 0.28 
               
               
                 Tc011095-16 
                 Positive 
                 0.44 
                 AT4-0063 
                 Negative 
                 0.155 
               
               
                 Tc011095-17 
                 Positive 
                 3 
                 E4-0051 
                 Negative 
                 0.162 
               
               
                 Tc011095-18 
                 Positive 
                 1.651 
                 E4-0059 
                 Negative 
                 0.176 
               
               
                 Tc011095-19 
                 Positive 
                 0.19 
                 E4-0068 
                 Negative 
                 0.241 
               
               
                 Tc011095-20 
                 Positive 
                 0.916 
                 E4-0071 
                 Negative 
                 0.127 
               
               
                 Tc011095-21 
                 Positive 
                 0.715 
                 C4-0072 
                 Negative 
                 0.101 
               
               
                 Tc011095-22 
                 Positive 
                 1.336 
                 C4-0088 
                 Negative 
                 0.141 
               
               
                 Tc011095-23 
                 Positive 
                 1.037 
                 C4-0090 
                 Negative 
                 0.078 
               
               
                 Tc011095-24 
                 Positive 
                 0.332 
                 C4-0096 
                 Negative 
                 0.162 
               
               
                 Tc011095-25 
                 Positive 
                 0.413 
                 C4-0101 
                 Negative 
                 0.181 
               
               
                 Tc011095-26 
                 Positive 
                 0.266 
                 C4-0105 
                 Negative 
                 0.702 
               
               
                 Tc011095-27 
                 Positive 
                 1.808 
               
               
                 Tc011095-28 
                 Positive 
                 0.238 
               
               
                 Tc011095-29 
                 Positive 
                 0.266 
               
               
                 Tc011095-30 
                 Positive 
                 1.563 
               
               
                 Tc011095-31 
                 Positive 
                 0.352 
                 Sensitivity 
                 33/48 
                 68.75% 
               
               
                 Tc011095-32 
                 Positive 
                 0.208 
                 Specificity 
                 24/26 
                 92.30% 
               
               
                 Tc011095-33 
                 Positive 
                 0.656 
                 Mean Pos. 
                 0.9188 
               
               
                 Tc011095-34 
                 Positive 
                 1.281 
                 Std Dev Pos. 
                 0.79 
               
               
                 Tc011095-35 
                 Positive 
                 0.907 
                 Mean Neg. 
                 0.1508 
               
               
                 Tc011095-36 
                 Positive 
                 0.429 
                 Std Dev Neg. 
                 0.06695 
               
               
                 Tc011095-37 
                 Positive 
                 0.454 
               
               
                 Tc011095-38 
                 Positive 
                 0.725 
               
               
                 Tc011095-39 
                 Positive 
                 0.703 
               
               
                 Tc0394-7  
                 Positive 
                 0.186 
               
               
                 Tc0394-8  
                 Positive 
                 1.06 
               
               
                 Tc0394-9  
                 Positive 
                 1.813 
               
               
                 Tc0394-10 
                 Positive 
                 0.131 
               
               
                 Tc0394-11 
                 Positive 
                 1.631 
               
               
                 Tc0394-12 
                 Positive 
                 0.613 
               
               
                 Tc0394-13 
                 Positive 
                 3 
               
               
                 Tc0394-14 
                 Positive 
                 0.268 
               
               
                 Tc0394-15 
                 Positive 
                 2.211 
               
               
                   
               
             
          
         
       
     
     Example 5 
     Serological Reactivity of Peptide Combinations 
     This example illustrates the diagnostic properties of several peptide combinations. 
     The TcLo1.2 peptide (contained within SEQ ID NO:35) was tested in combination with the synthetic peptide TcD and also the dual epitope peptides D/2 (which contains the TcD and the PEP-2 sequences) and D/E (which contains TcD and TcE sequences). These combinations were compared with the individual peptides as well as the tripeptide 2/DI/E, which contains TcD, TcE and PEP-2. The TcD sequence used was Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser (SEQ ID NO:53), the TcE sequence was Lys Ala Ala lie Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Thr Ala Pro Ala (SEQ ID NO: 55), and the PEP2 sequence was Gly Asp Lys Pro Ser Pro Phe Gly Gln Ala Ala Ala Gly Asp Lys Pro Ser Pro Phe Gly Gln Ala (SEQ ID NO: 57). 
     The data are shown in FIG.  6 . The results show that TcLo 1.2 can augment the reactivity of TcD, D/2 and D/E, as summarized in Table 2. 
     Table 2 
     Sensitivity of Peptide Combinations in the Detection of  T. cruzi  Infection 
     
       
         
               
             
               
               
               
             
           
               
                 TABLE 2 
               
             
             
               
                   
               
               
                 Sensitivity of Peptide Combinations in the Detection of  T. cruzi  Infection 
               
             
          
           
               
                   
                 Peptides 
                 Number of Positives 
               
               
                   
                   
               
               
                   
                 TcD 
                 62/67 
               
               
                   
                 TcE 
                 50/67 
               
               
                   
                 PEP-2 
                 66/67 
               
               
                   
                 TcLo1.2 
                 61/67 
               
               
                   
                 TcD + TcLo1.2 
                 66/67 
               
               
                   
                 D/2 + TcLo1.2 
                 67/67 
               
               
                   
                 D/E + TcLo1.2 
                 67/67 
               
               
                   
                 2/D/E 
                 67/67 
               
               
                   
                   
               
             
          
         
       
     
     These results demonstrate the use of  T. cruzi  antigens as described herein to enhance the serodiagnostic properties of other antigens. 
     Example 6 
     Serological Reactivity of TcE Repeat Sequences 
     This example illustrates the diagnostic properties of several TcE repeat sequences. 
     The repeat sequence region of the recombinant TcE contains several degeneracies, resulting in residues where an A (alanine), T (threonine) or I (isoleucine) can be present in the repeat sequence. In order to represent all degeneracies, the original sequence for the synthetic TcE peptide was made with an A, T and I in a single peptide containing three repeats (see Example 5). In order to further epitope map the repeat region and to determine the number of repeats required for serological activity, the following peptides were prepared as described in Example 2: 
     
       
         
               
               
               
             
           
               
                 original TcE 
                 KAAIAPAKAAAAPAKAATAPA 
                 (SEQ ID NO:55) 
               
               
                 TcE(3A) 
                 KAAAAPAKAAAAPAKAAAAPA 
                 (SEQ ID NO:58) 
               
               
                 TcE(3T) 
                 KAATAPAKAATAPAKAATAPA 
                 (SEQ ID NO:59) 
               
               
                 TcE(3I) 
                 KAAIAPAKAAIAPAKAAIAPA 
                 (SEQ ID NO:60) 
               
               
                 TcE(2A) 
                 KAAAAPAKAAAAPA 
                 (SEQ ID NO:61) 
               
               
                 TcE(AT) 
                 KAAAAPAKAATAPA 
                 (SEQ ID NO:62) 
               
             
          
         
       
     
     The serological reactivity of these peptides was then compared. A total of 24 positive and 21 negative sera were tested with each of the TcE variants as the solid phase in an ELISA assay performed as described in Example 3, using 25 ng/well of peptide. The reactivity of the different peptides is shown in FIG.  7 . The highest reactivity was seen with the 3-repeat peptide in which each repeat contained an A at the degenerate residue (TcE(3A)). This peptide displayed even higher reactivity than the original TcE sequence containing an A, T and I residue in the three repeats. The 3I and 3T variants by contrast were essentially negative with the  T. cruzi  positive samples tested. The sequence containing two repeats with A (TcE(2A)) was clearly less reactive than the 3A sequence and the two repeat sequence with an A and a T (TcE(AT)) was negative. Based on a cutoff of the mean of the negatives plus three standard deviations, the original TcE (A,T,I) detected 17 out of 24 positives and the 3A variant detected 19 out of 24 positives. It also appears that to obtain maximal serological activity at least three repeats are required. 
     Example 7 
     Serological Reactivity of Multi-epitope Peptide Combinations 
     This example illustrates the diagnostic properties of several multi-epitope peptide combinations. 
     Two dipeptides PEP-2/TcLo1.2, which contains the PEP-2 (SEQ ID NO:57) and TcLo1.2 (SEQ ID NO:35) sequences, and TcD/TcE, which contains the TcD (SEQ ID NO:53) and TcE (SEQ ID NO:55) sequences, were synthesized as described above in Example 2. The reactivity of these two dipeptides with  T. cruzi  antibody-positive sera was compared to that of the tripeptide 2/D/E. ELISA&#39;s were performed as described in Example 3 using PEP-21/TcLo1.2 at 250 ng/well and TcD/TcE at 50 ng/well. The results of this study are shown in FIG.  8 . One  T. cruzi  positive serum found not to react with the tripeptide 2/D/E was used in screening for the TcLo1.2 epitope. This serum was detected by the TcLo1.2 epitope and also by the dipeptide mix (PEP-2/TcLo1.2 together with TcD/TcE) as expected. 
     A tetrapeptide containing the four immunoreactive  T. cruzi  epitopes PEP-2, TcD, TcE and TcLol.2 in a linear sequence, herein after referred to as 2/Lo/2E/D (SEQ ID NO:63) was synthesized as described in Example 2. This tetrapeptide was coated at 100 ng/well and its reactivity with  T. cruzi  positive and negative sera was assayed as described in Example 3. The reactivity of the tetrapeptide 2/Lo/2E/D is shown in FIG.  8 . The one  T. cruzi  positive serum found not to react with the tripeptide 2/D/E was detected by the tetrapeptide as expected. 
     The four immunoreactive  T. cruzi  epitopes PEP-2, TcD, TcE and TcLo1.2 may also be linked into one reagent by the use of a ‘branched’ peptide originating from a lysine core residue. Orthogonal protection of the lysine, for example employing 9-Fluorenylmethoxycarbonyl (Fmoc) on the a-amino group and 1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde) on the E-amino group, is used to permit selective deprotection of one amino group in the presence of the other, thereby allowing the synthesis of the first peptide chain from either the α- or ε- group on the lysine. This first peptide chain is terminated with a protecting group that is not removed during the course of the synthesis of the second peptide chain. For example, a tert-Butoxy carbonyl (Boc) amino acid could be used with the Dde and Fmoc combination. The remaining lysine amino protecting group is then removed before a second amino acid chain is synthesized from the second amino moiety. For example, ε-Dde is removed with 20% hydrazine. Cleavage of the branched peptide from a solid support and removal of the N-α-Boc moiety is carried out using trifluoroacetic acid, following standard protocols. Using this approach two independent amino acid sequences can be built from a ‘core’ lysine residue, as shown below, thus allowing various combinations of TcD, TcE, PEP2, TcLo1.2, and other epitopes to be coupled to the core residue. Purification of the resulting peptide is performed as described in Example 2.                           
     Example 8 
     Preparation of Multi-epitope Peptide Combinations using Recombinant DNA Technology 
     This example illustrates the preparation of a fusion polypeptide (hereinafter referred to as TcF) of the peptides PEP-2 (SEQ ID NO: 57), TcD (SEQ ID NO: 53), TcE (SEQ ID NO: 55) and TcLo1.2 (SEQ ID NO: 35) using recombinant DNA technology. 
     The TcF polypeptide fusion was created by synthesizing overlapping phosphorylated oligonucleotides, annealing the matched oligonucleotide pairs to create double stranded DNA, ligating the annealed pairs with vector DNA that was cut with appropriate enzymes, and transforming into suitable bacteria host strains (XL2, Stratagene, La Jolla, Calif.) for sequencing. Once the correct sequence was obtained, the construct was subcloned into a modified pET28 vector and transformed into BLR pLYS S (Novagen, Madison, Wis.) for expression and purification. 
     For construction of the PEP2-TcD fusion, the matched pairs of oligonucleotides PDM-95 (SEQ ID NO: 66) and PDM-98 (SEQ ID NO: 67); PDM-96 (SEQ ID NO: 68) and PDM-99 (SEQ ID NO: 69); and PDM-97 (SEQ ID NO: 70) and PDM-100 (SEQ ID NO: 71) were synthesized, kinased and annealed. These three pairs of annealed oligos were then ligated, digested with EcoRI (New England Biolabs, Beverly, Mass.) and cloned into a modified T vector construct with Eco72I and EcoRI. For construction of the PEP2-TcD-TcE fusion, the following matched pairs of oligonucleotides were synthesized, kinased and annealed: PDM-103 (SEQ ID NO: 72) and PDM-105 (SEQ ID NO: 73); and PDM-104 (SEQ ID NO: 74) and PDM-106 (SEQ ID NO: 75). These two pairs of annealed oligos were ligated into the pT7ΔL2PEP2-TcD construct cut with Eco47III (New England Biolabs) and EcoRI. 
     For construction of the PEP2-TcD-TcE-Lo1.2 fusion, the two matched paris of oligonucleotides PDM-108 (SEQ ID NO: 76) and PDM-I 10 (SEQ ID NO: 77); and PDM-109 (SEQ ID NO: 78) and PDM- 110 (SEQ ID NO: 79) were synthesized, kinased and annealed. These two pairs of annealed oligonucleotides were ligated with the pT7ΔL2PEP2-TcD-TcE construct which had been cut with EagI, treated for blunt ends with T4 DNA polymerase and then cut with EcoRI. Due to an internal EagI site in the pT7ΔL2 vector, a PCR reaction was performed with the ligation mix as template in order to clone the full length PEP2-TcD-TcE-Lo1.2 construct. PCR was accomplished with the primers PDM-101 and PDM-107 (SEQ ID NOS: 80 and 81, respectively) using the following conditions: 
     96° C. 2 minutes 
     96° C. 15 seconds 61° C. 15 seconds, 72° C. 1 minute×40 cycles 
     72° C. 4 minutes. 
     Pful DNA polymerase (Stratagene, La Jolla, Calif.) was used for the PCR reaction. Following PCR, the DNA was subjected to an ethanol precipitation, digested with Smal and EcoRI, and ligated into a modified T vector construct which had been digested with Eco72I and EcoRI. 
     The resulting clone was digested with Hind III (Gibco BRL, Gaitherburg, Md.) and Sph I (New England Biolabs), treated with T4 DNA polymerase for blunt ends and then religated in order to delete the vector&#39;s internal Eag I and Nsi I sites. This new clone was then digested with Eag I and Nsi I, treated with T4 DNA polymerase for blund ends, and religated in order to create a stop codon in frame at the end of the TcLo1.2 sequence. This clone was digested with NdeI and Eco RI, and subcloned into a modified pET28b vector cut with the same enzymes. 
     The resulting expression construct was transformed into BLR pLys S  E. coli  (Novagen) and grown overnight in LB broth with kanamycin (30 ug/ml, Sigma, St. Louis, Mo.) and chloramphenicol (34 ug/ml Sigma). The overnight culture (12 ml) was used to inoculate 500 ml of 2XYT with the same antibiotics and the culture was induced at an OD560 of 0.3-0.6 with IPTG to a final concentration of 1.0 mM. Four hours post-induction, the bacteria were harvested and sonicated in 20 mM Tris (8.0), 100 mM NaCl, 0.1% DOC, 20 ug/ml Leupeptin and 20 mM PMSF followed by centrifugation at 26,000×g. The fusion protein was found in the soluble supernatant after sonication. The supernantant was bound to a Pro-bond nickel resin column (Invitrogen, Carlsbad, Calif.). The column was washed with 50 ml of 20 mM Tris (8.0), 100 mM NaCl wash buffer and eluted with an increasing imidazole concentration. Specifically, the elutions were made with 50 mM, 100 mM and 500 mM imidazole in the 20 mM Tris (8.0), 100 mM NaCl wash buffer. The eluates containing the protein of interest were pooled and dialyzed against 10 mM Tris (8.0). 
     After dialysis, the protein was concentrated, sterile filtered and tested for endotoxins. Test results indicated a high level of endotoxin contamination. The sterile filtered protein was therefore purified over a High Q anion exchange column (Biorad, Hercules, Calif.), binding in 10 mM Tris (8.0) and eluting with a NaCl gradient up to 1 M in 10 mM Tris (8.0). The elutions containing the protein of interest were pooled and dialyzed against 10 mM Tris (8.0). After dialysis, the protein was reconcentrated, sterile filtered and a BCA assay (Pierce, Rockford, Ill.) was performed to determine protein concentration. 
     The reactivity of the recombinant fusion polypeptide TcF with sera from  T. cruzi  patients and from normal donors was examined by ELISA as described above. As shown in FIG. 1 1 , the reactivity of TcF was found to be very similar to that of the branched synthetic tetrapeptide 2/D/E/Lo1.2. 
     It is envisioned that the order of the peptides in the recombinant fusion polypeptide TcF could be altered without significantly changing the activity of the polypeptide. Also, the inclusion of a Gly-Cys-Gly linkage between the peptides, as was employed in the synthetic tetrapeptide 2/Lo/2E/D, may enhance solid phase binding without significantly affecting the activity of the polypeptide. 
     Example 9 
     Comparison of the Serological Reactivity of TcHi29 and TcE 
     The antigen TcHi29 (SEQ ID NO:52) was shown to be a polymorph of the TcE repeat sequence. A TcHi29 peptide was synthesized that had the following sequence as compared to TcE. 
     
       
         
               
               
               
               
             
           
               
                   
                 TcE 
                 KAAIAPAKAAAAPAKAATAPA 
                 (SEQ ID NO:55) 
               
               
                   
                 TcHi29 
                 KTAAPPAKTAAPPAKTAAPPA 
                 (SEQ ID NO:64) 
               
             
          
         
       
     
     FIG. 9 shows a comparison of the reactivity of these two related seqences with sera from  T. cruzi  positive patients as well as from other disease categories, as determined by ELISA using the procedure described above. The data indicate little or no cross reactivity with the other disease groups tested but the distribution of reactivity amongst the  T. cruzi  positive sera partially overlapped for the two peptides. Of the 53 consensus positive samples tested, TcE detected 31/53 and TcHi 29 36/53. Within this group TcE and TcHi29 both detected 24 of the same sera. TcE detected 7 positive sera not detected by TcHi29, which in turn detected 12 positive sera missed by TcE. A dipeptide, TcD/FcHi29, was also synthesized and used in combination with the PEP-2/TcLo1.2 dipeptide in ELISA (100 ng/well TcD/TcHi29, 250 ng/well PEP-2/TcLo1.2) and compared with the TcD/TcE plus PEP-2/TcLo1.2 dipeptide combination. As shown in FIG. 10, the data indicates that the overall activity of the two mixes are similar for both the  T. cruzi  positive and negative populations studied and suggests that, in such peptide combinations, TcHi29 can be considered to be an alternative to TcE. 
     From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention. 
     
       
         
           
             81 
           
           
             
               518 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             1
CGGGAAAAGA AGGCTGTTAC GACGCACGAG CTTGGCTTTG AGGGCGAGGA CTGGGACTAC     60
GTGCTGGAGC GGCGGCGCGC GGAGGTGAAG GACGTGCTGG CCGTCGAGAC GGCGCGGGCG    120
TTGGGACTCG AGCGTGAGGA CGTGCTGGAG GTGGAGGTCG ACGCAGTGCC TCGGAGCCTC    180
ATTGCGTTTG TCACGGTCCG TCATCCATCA CTGCTGAGCG ACCGCAGGTG GAAGAGACGC    240
TGGCGCGCTG CGAGTACAGG AAATTGTGGG CGCTGTACGA GACGCGGCCA CTGGAGTCGT    300
CAGTGCTGAT GAGGCGGTTT GAGGGCGACG ACTGGGACCT CGTGGTTGAC AACAACCGCA    360
GGAAGCTTGA GGACGCGTTC AGCAGGGAGA CGGCCGCGCA CTGGGCGTGT CGCCGAGGCA    420
GGTTGTGCTT CTGGACTGCA GGGTTGGCAG CCTTCTCATG GTATTCAAGG TGCTTGGATG    480
CGCCATGAGC GACGCAGAGA TCACGGAACG GACCGAGG                            518 
           
           
             
               560 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             2
CGGCGGTAGT CTGCGATGCT GTGGACCGAC GCATTGAAAT ACACACCGTC TTCGGCGTTC     60
CTTTTTTTTA TATGTTTTTT TTTATTGAGA AGATGTCTTG TTTGTTGTTG TTTTTTTTCA    120
GTTTTTATGA TACGAGCAGT TTGTCCGACT GCATTCATGC AGTGATTGGT AATTCTTTCT    180
ATTCTTTGGA ATTATGGCGA TATTATTCTT GTCTTTTAAA ATTCTTACAA CCAATTGTGC    240
CTTAGAGTTT CCTGCTTAGT TGCTATTAAC ACACTGTTAG GAACGCGAAA CCATGCAGAT    300
CTTCGTGAAG ACACTGACGG GCAAGACGAT CGCGCTCGAG GTGGAGTCCA GCGACACCAT    360
TGAGAACGTG AAGGCGAAGA TCCAGGACAA GGAGGGTATC CGCCGGACCA GCAGCGCCTG    420
ATCTTCGCTG GCAAGCAGCT GGAGGACGGC CGCACGCTCG CAGACTACAA CATCCAGAAG    480
GAGTCCACGC TGCACCTTGT GCTGCGCCTG CGCGGCGGCA TGCAGATCTT CGTGAAGACA    540
CTGACGGGTA AAGACGATCG                                                560 
           
           
             
               436 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             3
CGGCTGCCTC CTCTGCTTCC TTCCTCGGAC GTGCCCGAAG GCATGGAGCT GCCTCCTCTG     60
CTTCCTTCCT CGGACATACC CGAAGGCATG GAGCTGCCAC CTCTGCTTCC TTCCTCGGAC    120
GTACCCGCGG GCATGGAGCT GACACCTCTG CTTCCTTCCT CGGACGTGCC CGAAGGCATG    180
GAGCTGCCAC CTCTGCTTCC TTCCTCGGAC GTACCCGCGG GCATGGAGCT GCCACCTCTG    240
STTCCTTCCT CGGACGTACC CGCGGGCATG GAGCTGCCTC CTCTGCTTCC TTCCTCGGAC    300
GTACCCGCGG RCATAGAGCT GCCACCTCTG ATTTCCTNCC TCGGACGTAC CCNCAGGNAT    360
GGAGATGNCT CCTCTGNTTC CTGCCTCGGA CGTNCCCNAA GGNATAGAGN TGCNCCTCTG    420
NTTCCTNCCT CGGAAG                                                    436 
           
           
             
               373 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             4
CCTCAGGGGC TCTTGGCGTT CCTTTTTTTC TTGTTGTTTT GAGTTTTTTT TTCTTTTGTT     60
TTGGTTTGTC GTCTCTGTTT TTATGTGCGT TGTTTTCGGT TTTTCTTTTT GTTCTTCCTG    120
CCTGTCATGT GACTAGTTTT ATGTTTTCCA GGCCGACCGT CACTCAATTT TTTTATTTTT    180
ATTTTTATTT ATTTATTTGA CCCGCCTTTC TCTGTAGTTT ACGAGAGTTT AGATTTTTAT    240
TGATTGGTAG TTTAGGGCCA TCAGGCGGGA GGGGCGAGTC TGGCGGAAGA CAAAACAAAA    300
TACGATGGAC TCGACCAACA GCATCGAGAA ATCGCTTCTG ATGGAGATGG AGCGGGAGGT    360
TGAGAGGGCG AGG                                                       373 
           
           
             
               560 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             5
CAGAAAAAGA ACGTAGATTT CCAACCAAAA CAGCAAGAGC GGATCCAACA ACGACCAAAC     60
AACTCATTAT TCGAGCTCTC CAAAATATAT CGCTTGCCTT CGGGATTGAA CCCTCATCTA    120
CAGTAAAATA CGCCGAAAGC ACGCAAGAAG AAAATGGAAA ACGTTCACAA AGTGAGGCCG    180
AGGAGCGTGC ACGGCGGGAG GCTGAGGAAC GAGCACGGCG AGAGGCTGAG GAACGAGCCC    240
AACGAGAGGC TGAGGAACGA GCCCAACGAG AGGCTGAGGA ACGAGCACGG CGGGAGGCTG    300
AGAAGCGTGC CCGGCGAGAG GCTAAGGAAC GAGCATGGCA AGAGGCCGAA GAACGAGCCC    360
AACGAGAGGC TGAGGAGCGT GCCCGGCGAG AGGCTGAGGA GCGTGCCCGG CGAGAGGTTG    420
AGGAGCGTGC CCGGCAAGAG GCTGAGGAAC TCGCACGGCA AGAGTCTGAG GAACGTGCAC    480
GGCAAGAGGC CGAAGAACGA GCATGGCAAG AGGCTGAGGA GCGTGCCCAA CGAGAGGCTG    540
AGGAGCGTGC TCAACGAGCG                                                560 
           
           
             
               440 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             6
GCCTCCTGCA ACTCGAGCTG GCAGCGTGGA GGTGCNGCAG GAACTCTCAA NAGANGACGG     60
CTCTCCCTCG ATANCNTTCG GAGTGACTTN GACTGTTGCG CCNTTTCCGT NTCACTATTT    120
CTATTGCTTT TAATTTGCTG GAGAGGCGCG TGTAGGAGGG AAAGAGTAGT AACATGGCAG    180
AATCATCAAA AACGATGTTG CGTTAGTAGA GAGGAGGGAA ACATCGAGAC GTTGAGGGTT    240
GCGACGGNCA AAATTATGTA CATTTACCTG AATTAGGATA AGACTTCATA TGGCATAAAC    300
TCGTGGCGTT GTTGGTGGTT ATAACAAGCA ACGGTGACGA TGTCTTAGGC TACACTGCTG    360
CACTCAAAGA GTTTTACAGG TACTTGCGGG ATATTTGTTC CTGTGAGTTT GTTTTCTATT    420
GTAATTTATT NNGTCTCAAT                                                440 
           
           
             
               1915 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             7
CGATGCGTCT GTCGTAGACC TGGGAGGCGA GGCCCATGGG ACACACTATG CCTTTTTGCC     60
CGATGTGATC AAGGGGATTG CGCAGGAAGA GCTGTACCTG GAAGACGATG CGTACTTCCA    120
GGAGTTGCTT GCGAGGTATA AAGAACTTGT CCCTGTGGGT GCCGAGCCAA CCGAGCCACG    180
CGCAAAGCAG TTGCGCGAGC AAATGCGGAT ACGGGCTGGG CAGCTTGCTG TTGACACCCG    240
AAAGCTTCAT GCGGCCGAAG AGCGGGCTGC ATCGCGGATG GCGACACTTT ACCCGTTTGT    300
GGGCTCGGCG CCGCTGGGAG TTGCTCTGTG GAATATCCCC GTGGAGGCGG ACGAAGAGTT    360
CTGTGCACTT CTGCTGAAGC GCGAAGAAGC GCTGGCGGGG AAGTCAGGGT CCGTCCACGA    420
AGTGGAATCT GCGCTGAGCG CGCGTGCGGA AGCGATGGCG AAGGCGGTGC TGGAGGAGGA    480
GGAGGCGCTT GCGGCGGCAT TTCCATTTCT GGGGCGGAGT GTTAAGGGAG CCCCTCTGCG    540
TGAGTTGGCT CTCATGTCTG ATCCCAATTT TGCGGAGCTG GCGACACGGC ACGCGCAGGA    600
GGCGACCTCG GGCGATGCGG CGGGTATTTT GCGCCTTGAG CAGGAGCTGC GTGACCAGGC    660
ATGTCGCATA GCACGTGAGG TGCGAGTGGC TCGGCGGCTT GACGCCGTCG CAATGAGGAC    720
CTGCACGAGC GGTACCCGTT TCTTCCCGAG GAGCCGGTGC GCGGCATTCT TCTTGGTGCT    780
GTGCGTCCGG TGCAGCAACC GGCGTTCCGC GAGCTTTCAA ACAAGTTGGA TGAGCAGCGC    840
CGGGACCCGA CACGCAACGC AGCCGCGATC CGCACGACGG AGGAGCAGAT GACTGCGTTG    900
GTGGTGCGAC TGGCTGAGGA GCGCGCGGAG GCGACGGAGA GGGCGCATGA GCAGTACCCG    960
TTTCTCCCAC GACGTGTGCT GGGCGTGCGC CTTGGTGACA TCTCGCTGCA GGAGGATGAT   1020
GTGTTGTCAC AGCTGGCGCG GCGTCGTGTG CGGCAGCTAA GAAACTCCAA GACGGCGATT   1080
GACGCACACG CAACTGAAGA AGAGATGATA AGGCGCGCAG AGGAGCTGGC TCGCAACGTG   1140
AAGCTTGTCG ACGCATACCG TGGGAATGGG AACGAGTACG TGCGTGCCTG CAACCCGTTT   1200
CTCGTGTACG AGGACCGCAA GTGCGTCCTC CTGAGTGAGC TGCCGCTTGC CGGTGGCGAC   1260
GTGTACCAGG GCTTGTTCCG GGATTATCTG ACTGCGCTGG AGGACGCCGA GGCAAATGCA   1320
CCGCGGATCG CGGAGCTGGA GAATGCGCTT CGGTCCCGTG CGGATGAGTT GGCGCTGGAG   1380
GTTTGCGAGA GGGACGCGCG GTTGTTGCAT TACTCATTCC TCTCGGCCCA GGATGTTCCT   1440
GGTTGGTCTG AAGCACTGCT GCATGACGCG GAGTTTCAGC AGCTACGTGA GCGTTACGAG   1500
GAACTGAGCA AGGATCCACA GGGGAACGCC GAGGCATTGC GTGAGCTTGA GGATGCAATG   1560
GAGGCTCGGA GCAGAGCCAT TGCGGAAGCG TTGCGGACTG CAGAGCGACT AATCCACTGA   1620
GCAGGCGAGG CTGAAGACGC CGTCACAGGC GGGGTCTGGC GTGTCCGCGG GTGATCGAAT   1680
GCATGGCAGC GAGCATGCGG ATCTCGCGCA TGAAGGGGGA AGCACGGCTG GCGGCACCAT   1740
GAGGGGGGCA GAGTCTGTCT CCAAGAGCAG TGGGAAACAC TCTCAAGGTC GGTCTCGCAT   1800
GCGTCTGTCG TAGACCTGGG AGGCGAGGCC CATGGGACAC ACTATGCCTT TTTGCCCGAT   1860
GTGATCAAGG GGATTGCGCA GGAAGAGCTG TACCTGGAAG ACGATGCGTA CTTCG        1915 
           
           
             
               400 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             8
TTACCAAGCT GAGATAGATA AAAGGCTGCA GGAGCAGCTT GCCCCTGAGA GGATGAGGGC     60
TCTTTCCGCA TTTCTTTCGG AGTGACTTTG ACTGTTGCGC CGTTTCCGTG TCACTATTTC    120
TATTGCTTTT AATTTGCTGG AGAGGCGCGT GTAGGAGGGA AAGAGTAGTA ACATGGCAGA    180
ATCATCAAAA ACGATGTTGC GTTAGTAGAG AGGAGGGAAA CATCGAGACG TTGAGGGTTG    240
CGACGGNCAA AATTATGTAC ATTTACCTGA ATTAGGATAA GACTTCATAT GGCATAAACT    300
CGTGGCGTTG TTGGTGGTTA TAACAAGCAA CGGTGACGAT GTCTTAGGCT ACACTGCTGC    360
ACTCAAAGAG TTTTACAGGT ACTTGCGGAT ATTTGTTCCT                          400 
           
           
             
               936 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             9
GCCTCCTGCA ACTCGTGCTG GCAGCGTTGA AGTTCGGCAG AAATCTCAAC AAACGCCTTC     60
TGTCCCTCGG AAACCTTCCC GTTAAGAGAC ACAAGCAGTT CAATGAGCGA CATGGTCGCT    120
TCGGACACGT CCAATGCTTT CATGGTTTGT TCCAGCCGCC GCTGAAAGTT ATCCACACAT    180
GAGAACAACA AAGACAAATC TAAATCGGCG TCGCCGTGCT CATACACATC AAACGCCACC    240
GTCTCGCCCA AAACATTCAA AAAGTTCACC AAAAAGTTTA CAAGCTTACT CAAATTGTCA    300
CGAAGTGAGC TAACGGTAAT TTCTAAACTT CCATTTCTTG CGTCATCCCT AGCCTTCGCC    360
GCGACTACCT TCTCCTTCCA TAGCACTAGC TTCTCCTCCA CCAAACGAAT ACCGCTCTCC    420
TTTTCTTTCA CAGCAACCTC ACATTCCCTT TCAATTTCAT TCAACCTAAT TGGATTATTT    480
TCTTAAACGA CTTGCCGTGC CCTCCTCGGG CTGATGAAAG GCCTCGCCCA GCTGCGCACG    540
CAGATTCACG GTGTCCGCCC CGTTCTGCTC CCGGAGAGCG GCCAGTTCCT CGGTGGTTCG    600
CTTCAGCTCG CGATGCACCT CCTCGCGCTG CTGCAAGGCC TCGTCCAGCT GCGCACGCAG    660
ATTCACGGTG TCCGCCCCGC TCTGCTCCCG GAGAGCGGGC AGTTCCTCGG TGGTTCGCTT    720
CAGCTCGCGA TGCACCTCCT CGCGCTGCTG CAAGGCCTCG TCCAGCTGCG CACGCAGATT    780
CACGGTGTCC GCCCCGCTCT GCTCCCGGAG AGCGGGCAGT TCCTCGGTGG TTCGCTTCAG    840
CTCGCGACGC ACCTCCTCGC GCTGCTGGAA GGCCTCGCCC AGCTGCGCAC GCAGATTCAC    900
GGTGTCCGCC CCTCTCTGCT CCCGGAGGGC GGGCAG                              936 
           
           
             
               702 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             10
ACTTGAAAGA NTGACCCAAT AATNGGGTTC CTTATTGTGC CACCCCAAAT AAACCCGTAA     60
CCAATTTGTG GCTGGGATGG ATCCCCCCAC NCTCTTTGAC NCATGTCAAG AGTANATGGG    120
ACGTCAAAGT CACTTAGAGA GGGATTCATG GGTNCCATTG ATCACAAGAG CCTNCTGGAA    180
GACCCCCGTG AAGATAACCC AATGAGATTT ATCGTCTGCA TAAGATCACA CGAGGCGGTA    240
TTAGCAATTA TCTTCACAGA TTCTTTTTCT TGTGATGGTG GCTTGCGGTA GTTTGTCATC    300
ATTGTTTTCT GAATGCAATG AAGCACACGA CTTGTAATAC GTTCTCCATG TCTTTCAATC    360
GTTTCCAACG CCTCCACAAT GTCTGCAGGA TCCCCAGGAA GGTCAGCAGT CATCAGAAGC    420
TCTTCACATG AACGCCGTAA ACTAGGATCA CGCTCAACAA GGCTAGCAAT CGCATTTGCC    480
ATTCTCGGAT TCCACTTGCA AAACCACTCC GGAAGTTTAT TTCCACGACT GACCTCTGTC    540
ATAATGTTGA ACCTCTCCCT AAAGCCTTTA CCCGCCACGG CAAGCCACAT CTCAAGAGCT    600
ATCATACCCA GGCTGTATTC ATCCACTTTA AAGTCGTAGT CTTCCCCTCG CTCTTGCTCT    660
GGGGCACAGT ACAACACAGA ACCCAAGTTT CCTGTAGGAC CG                       702 
           
           
             
               510 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             11
CGAGTATTCC TGTGGAAATT GATATTAGAA ACCAGGACTT TTCTTTTCTT GACCCGGCAC     60
CGGAGGGCAT TCCTATTCAG GACATACATC TTATGGGAGA TTCTGCATTT GCCGCATCTG    120
CGCGTGAGCG CATGAAACTG AAAAGAAATC CTGTTGCGAA TGCGAGCAAG ATCAGTGCCC    180
TTGAGGAGGA GATGGATCAA CGTGCTCATG TATTGGCTAA GCAGGTGCGT GACAAAGAGC    240
GCACTTTCCT TGATCCAGAG CCTGAGGGTG TTCCACTTGA GTTGCTTTCA TTAAATGAAA    300
ATGAGGCCTC ACAGGAATTG GAGCGAGAGC TTCGTGCCCT AAATCGCAAA CCCCGGAAGG    360
ATGCCAAAGC AATAGTTGCT CTTGAAGATG ATGTGCGTGA CGAACACACG TGCTTGCCAA    420
GGAGCTAAAG GAAAATGAGC GGAACATCTT TGTTGGCTCC ACAGCCTGAG GGTGTGCCGG    480
TGTCTGAGCT GTCGTTGGAT TTAGACGAGC                                     510 
           
           
             
               320 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             12
CGGTCGTGGC AGAGCCAAAG CCACCAACAG CAGGTGCCGA CGTGTGCGCG GCAGAGCCGA     60
AGCCACCAGC AGCAGGCGCC GAAGTGGTCG TGGCAGAGCC AAAGCCACCA GCAGCAGGTG    120
CCGACGTGTG CGCGGCAGAG TCGAAGCCAC CAACAGCAGG TGCCGACGTG GTCGTGGCAG    180
AGCCAAAGTC ACCAGTAGTA GGNGCCGACG TGTGNGTGGC AGAGNCANAG NCACCAGTAG    240
NAGGTGNCGA CGTNGTCGTG GNAGAGNCGA NGTCACCAGC AGGAGGTGNC GACGTNTGNG    300
NGGNAGAGGC GATGTCACCA                                                320 
           
           
             
               302 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             13
ATGCATCTCC CCCGTACATT ATTTTGCGGA AAATTGGATT TTTACGGGGA GGTGGGGTTC     60
GATTGGGGTT GGTGTAATAT AGGTGGAGAT GGAGTGCAGT GGGATAGGAT TAGAATGTAG    120
TTGGTGTAGT ACAGAGTTTA TATAGTATAG TGTTGATGTT ATTATACAAT GAGGTAAGAG    180
AATGGAGTGA GAAAGAGTAT GTTTGTTAGT TTGGTTGTTA ATGTTATGTA TTCATGTTAT    240
CAGTATATGT TGTATGTGTA TGGTGATAGC GGTGGGTGTA GCTGTATGTG GTAGGTTAGA    300
GT                                                                   302 
           
           
             
               298 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             14
CAGTTTCAAT TTCCTCTCCA CCTGATCCCG CTGTTGCAAA AGCGTCCTTG ATGTATCCTG     60
CTCCTTTGCC GCTAGCGCCT CCCTTGCTAA GCGCAGTTCC TCTTGCAGCC TCGCCTGCAC    120
CCGTTCCGCC TCCATTAATC TCTTCTCCCC GATTGCTTCT TTGGCGCGTA AATCCTCCAG    180
TTCCTTCTCT ATCAAAGTGT GCCTCCCATT CCTGATCCGC GACTCTTCAC AGGCTTCTTG    240
CTCCGCGTCA CGGAGACGCC TCTTGAGAGC CTCGTTCTTC TCTTCCAGGT CTTCTGGG      298 
           
           
             
               2144 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             15
CGCGGAATTC TTACCAAGCT GAGATAGATA AAAGGCTGCA GGAGCAGCTT GCCCCTGAGA     60
GGATGAAGGC TCTTTCCACA TTTCTTTGGG AGTGACCTTG ACTGTTGCGC CGTTTCCGTG    120
TCACTATTTC TATTGCTTTT AAATTGCTGG AGAGGCGCGT GTAGGAGAGA AAGAGTAGTA    180
ACATGGCGGA ATCATCAAAA ACGATGTTGC GTAAGTAGAG AGGAGGGAAA CATCGAGACG    240
TTGAGGGTTG CGACGGCCAA GATTATGTAC ATTTACCTGA ATTAGGATAA GACTTCATAT    300
GGTATAAAGT CGTGGCGTTG TTGGTGGTTA TAACAAGCAA CGGTGACGAT GTCTCAGTCT    360
ACACTGCTAC AATCAAAGAG TTTTACAGGT ACTTGTGGAT ATTTGTTCCT GTGAGTTTGT    420
TTTCTATTAT AATTTATTTT GTCTCAATTT TTTGTTTCCC CGCTTCCTAC GGTCTCTTTT    480
TTTCTTCGTT CTTGAAATTT CAATTATTGC TTAACCACAA GCATCCAGTA CTTCAACCTC    540
CCCATCAAAT GGTGTCGCTG AAGCTGCAGG CTCGTTTGGC GGCGGACATT CTCCGCTGCG    600
GTCGCCACCG TGTGTGGCTG GACCCTAATG AGGCCTCTGA GATTTCCAAT GCAAACTCGC    660
GCAAGAGCGT GCGCAAGTTG ATCAAGGATG GTCTGATTAT TCGCAAGCCT GTCAAGGTGC    720
ACTCGCGCTC CCGCTGGCGC CACATGAAGG AGGCGAAGAG CATGGGCCGC CACGAGGGCG    780
CTGGGCGCCG CGAGGGTACC CGCGAAGCCC GCATGCCGAG CAAGGAGCTG TGGATGCGCC    840
GTCTGCGCAT TCTCCGCCGC CTGCTGCGCA AGTACCGCGA GGAGAAGAAG ATTGACCGCC    900
ACATTTACCG CGAGCTGTAC GTGAAGGCGA AGGGGAACGT GTTTCGCAAC AAGCGTAACC    960
TCATGGAGCA CATCCACAAG GTGAAGAACG AGAAGAAGAA GGAAAGGCAG CTGGCTGAGC   1020
AGCTCGCGGC GAAGCGCCTG AAGGATGAGC AGCACCGTCA CAAGGCCCGC AAGCAGGAGC   1080
TGCGTAAGCG CGAGAAGGAC CGCGAGCGTG CGCGTCGCGA AGATGCTGCC GCTGCCGCCG   1140
CCGCGAAGCA GAAAGCTGCT GCGAAGAAGG CCGCTGCTCC CTCTGGCAAG AAGTCCGCGA   1200
AGGCTGCTGC ACCCGCGAAG GCTGCTGCTG CACCCGCGAA GGCCGCTGCT CCACCCGCGA   1260
AGACCGCTGC TGCACCCGCG AAGGCTGCTG CACCTGCCAA GGCTGCTGCT CCACCCGCGA   1320
AGGCTGCTGC TCCACCCGCG AAGACCGCTG CTCCACCCGC GAAGACCGCT GCTCCACCCG   1380
CGAAGGCTGC TGCTCCACCC GCGAAGGCCG CTGCTCCACC CGCGAAGGCC GCTGCTCCAC   1440
CCGCGAAGGC CGCTGCTGCA CCCGCGAAGG CCGCTGCTGC ACCCGCGAAG GCTGCTGCTC   1500
CACCCGCGAA GGCCGCTGCT CCACCCGCGA AGGCTGCTGC TCCACCCGCG AAGGCTGCTG   1560
CTCCACCCGC GAAGGCTGCT GCTGCTCCCG TTGGAAAGAA GGCTGGTGGC AAGAAGTGAA   1620
GCGCGCACTA GTACGACCAA CTTGTTTTTT TTTTTGGTAT TTAATATTTT CTGAGGAAGA   1680
AGTGGGTATT GAGGGTCTTT CTTTCCGCGT TTGTGTTGGT TTGTGGTGTT CGTGACATTA   1740
TAGTAGATCC AAAGTATTCT TCAGTGTCCC TTTTCCTTTT CTCCATCCTT TTTCCTATTT   1800
TTTGTTTGTC TTCTCTACGA TCTTTGTTGT CGTGTGACCT CCGCTGTATG GAACTGACGG   1860
CCGGCGTTGT GAGAGACGAT GTCGCACGTC ACGGCGGACC TGGAGTATTT TAAATGTGAC   1920
ATGTGCGGGG TGTATCTGCA CAAAGACATC TTTTGCGACC ATCGACGTGA GTGTAAAGGC   1980
CTTGATTCGA AAGAGCTGAA GAAGAGCCAG TGTCGTCAGA TCGGGATGGC ATTAGACAAG   2040
GAGGCACGGC ACCGAATTGC GTCACGAATG GCTGATGGAG CAACTCTCGT GCCTGTCGAG   2100
CTTGCAGAAC GACATCAACA GGCGCGTGTG CGGCGTAATG TGGC                    2144 
           
           
             
               456 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             16
TGTGCTGCAG AAGGAGAGGG ATGAAGCCGT GGCGGAGAAT GCCCAGCTGC AGAAGGAGAG     60
GGATGACGCC GTGGCGGAGA ATGCCCAGCT GCAGAAGGAG AGGGATGACG CCGTGGCGGA    120
GAATGCCCAG CTGCAGAAGG AGAGGGATGA CGCCGTGGCG GAGAATGCCC AGCTGCAGAA    180
GGAGAGGGAT GACGCCGTGG CGGAGAATGC CCAGCTGCAG AAGGAGAGGG ACGAAGCCGT    240
GGCGGAGAAT GCCCAGCTGC AGAGGGAGAG GGATGACGCC GTGGCGGAGG ATGCCCAGCT    300
GCAGAAGGAG AGGGATGAAG CCGTGGCGGA GAATGCCCAG CTGCAGAGGG AGAGGGATGA    360
AGCCGTGGCG GAGAATGCCC AGCTGCAGAA GGAGAGGGAT GACGTCGTGG CGGAGAATGC    420
CCAGCTGCAG AAGGAGAGGG ATGACGCCGT GGCGGA                              456 
           
           
             
               2446 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             17
TGAAGGCCGT TGATCCTTTT CAGGGAACGA CACCGCCGCC CTATAAATGG CAAGAAATGA     60
CTGGATCTGA GGCGGCAGCC GGCTCGCTTT GTGTACCCAG CCTTGCTGAG GTGGCCGGCG    120
GTGTGTTTGC CGTTGCTGAA GCTCAGCGCA GTGAAAGGGA CGAAGCCTGC GGCCATGCTG    180
CGATTGCAAC AACGCACATT GAGACGGGCG GTGGTGGCTC AAAGGCGATC TCGGCGATGG    240
ATGCAGGCGT TTTTCTCGTA GAACTTGTGG ATGCCGCCAG TGGTACGATC AGGACACGAG    300
AAAAGATGCA GCCAACGACA ATTGTGAGCG GCGACACTAT CTACATGGCC CTTGGGGACT    360
ACGAGAAGAA GACGTCTGGG GGTCGGGCTG CCGATGCAGA TGGCTGGAGG CTTTTACTGA    420
TGAGGGGAAC TCTCACTGAG GATGGTGGGC AGAAGAAAAT CATGTGGGGT GATATCCGTG    480
CAGTGGACCC TGTGGCCATC GGGCTTACTC AATTCCTGAA GAGGGTGATC GGTGGCGGAG    540
GATCGGGTGT TGTGACGAAG AACGGTTACC TTGTGCTTCC CATGCAGGCA GTAGAAAAGG    600
ATGGAAGGAG TGTTGTACTG TCCATGCGTT TCAACATGCG TATAGAAGCA TGCGAGCTCT    660
CGTCCGGTAC GACAGGTAGT AACTGCAAGG AACCATCCAT CGCGAATTTG GAAGGAAATC    720
TAATTTTAAT TACTTCTTGC GCTGCCGGCT ACTACGAAGT ATTCAGGTCC CTTGACTCTG    780
GGACAAGTTG GGAAATGAGT GGTAGGCCAA TTAGTCGCGT GTGGGGCAAC TCGTATGGTC    840
GAAAAGGGTA TGGCGTTCGC TGTGGCCTCA CCACCGTAAC CATTGAGGGA AGGGAAGTGC    900
TGCTTGTTAC CACGCCAGTG TATTTGGAGG AGAAAAATGG TAGGGGTCGG CTTCATCTTT    960
GGGTGACGGA CGGTGCACGT GTGCATGATG CTGGGCCGAT ATCCGATGCA GCTGATGACG   1020
CTGCTGCCAG TTCCCTGTTG TATAGCAGTG GGGGCAATCT GATTTCGCTG TACGAGAATA   1080
AGAGTGAGGG GTCATACGGT CTTGTTGCTG TGCACGTGAC TACGCAGCTG GAGCGGATAA   1140
AGACTGTGTT GAAGAGGTGG CAGGAGTTGG ATGAAGCCCT AAGAACGTGC AGATCCACTG   1200
CCACTATCGA CCCGGTGAGA AGGGGCATGT GTATTCGTCC CATTCTTACT GACGGGCTTG   1260
TTGGCTATTT GTCTGGTCTG TCGACTGGGA GTGAGTGGAT GGACGAGTAC CTCTGCGTGA   1320
ACGCAACTGT TCATGGGACG GTGAGAGGGT TCTCCAATGG AGTGACGTTT GAAGGACCCG   1380
GAGCAGGGGC GGGGTGGCCT GTTGCCCGAA GTGGACAGAA TCAACCGTAC CATTTCTTAC   1440
ACAAAACGTT CACTCTAGTG GTGATGGCGG TCATCCACGA TAGGCCGAAG AAACGCACCC   1500
CCATTCCTTT GATTCGTGTG GTGATGGATG ACAATGACAA GACTGTGCTA TTTGGTGTGT   1560
TTTACACCCA TGATGGGAGG TGGATGACTG TAATTCATAG TGGCGGTAGA CAAATACTTT   1620
CAACAGGGTG GGACCCAGAA AAACCGTGTC AGGTAGTGCT GCGACACGAC ACGGGCCATT   1680
GGGATTTCTA CGTTAACGCG AGGAAGGCTT ACTTTGGCAC CTACAAGGGT CTCTTCTCCA   1740
AACAAACAGT ATTTCACACA TCCAATTCCA CGGGGAGAGT GGGGAAGTTG CAGAGTCCAG   1800
CCATTTGTCA CTCTTCAACG CCCGTTTGTA TAACCGAAGA CTCAATTCCA AGCATCTAAG   1860
ATGGCTCATG GTCGGCGAGA CAGGCCCAAA ATACGATGAT GGCAGCTCTT ATTCTGCGAG   1920
TGCGTCCGAG GAAGGAAGCA GAGGTGGCAG CTCCATGCCC GCGGGTACGT CCGAGGAAGG   1980
AAGCAGAGGT GGCAGCTCCA TGCCTGCGGG TACGTCCGAG GAAGGAAGCA GAGGAGGCAG   2040
CTCCATGCCT GCGGGTACGT CCGAGGAAGG AAGCAGAGGA GGCAGCTCCA TGCCTGCGGG   2100
TACGTCCGAG GAAGGAAGCA GAGGTGGCAG CTCCATGCCT GCGGGCACTT CCGAAGAAGG   2160
AAGCAGAAGT GGCANCTCCA TGCCTTCGGG CTCTTCCGAA GAAGGAAGCA GAAGAGGCCG   2220
CTCCCTGCCT TCGGGTTCTT CCGAAGGAAG GAAGCAGAGG AGGCCCTCCC TGCCTGCGGG   2280
TTCTTCCGAA GAAGGAAACA GAAGTGGCNC TCCATGCCCG CGGGTTCTTC CGAGGAAGGA   2340
ACCAGAAGAA GCNCTCCCTG CCCGCNGGTT CNTCCNAAGA AAGAAACANA AGTTGGCCNC   2400
TCCCNGCCCC NNGTTTCTTC CNAANGAAAG AAACAAAAGT GGCCCC                  2446 
           
           
             
               345 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             18
GGGTACGTCC GAGGAAGGAA GCAGAGGTGG CAGCTCCATG CCTGCGGGTA CGTCCGAGGA     60
AGGAAGCAGA GGTGTCAGCT CCATGCCTGC GGGTACGTCC GAGGAAGGAA ACAGAGGAGG    120
CAACTCCATG CCTGCGGGTA CGTCCGAGGA AGGAAGCAGA GGTGGCAGCT CCATGCCTTC    180
GGGCACGTCC GAGGAAGGAA GCAGAGGTGG CAGCTCCATG CCTTCGGGTA CGTCCGAGGA    240
AGGAAGCAGA GGAGGCAGCT CCATGCCTGC GGGTACGTCC GAGGAAGGAA GCAGAGGTGG    300
CAGCTCCATG CCCGCGGGTA CGTCCGAGGA AGGAAGCAGA GGCCG                    345 
           
           
             
               835 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             19
GGCACGAGCT GTACTATATT GTAGGAGAGC AGCCATGGGT ATCGTTCGCA GCCGCCTGCA     60
TAAACGCAAG ATCACCGGTG GAAAGACGAA GATCCACCGG AAGCGCATGA AGGCCGAACT    120
CGGCCGTCTT CCCGCGCACA CGAAGCTTGG CGCCCGCCGC GTGAGTCCCG TCCGCGCCCG    180
CGGTGGGAAC TTCAAGCTCC GCGGTCTTCG CCTGGACACC GGCAATTTTG CGTGGAGCAC    240
AGAAGCCATT GCTCAGCGGG CCCGTATCCT CGACGTTGTG TACAACGCCA CTTCTAACGA    300
GCTGGTGCGC ACGAAGACGC TTGTGAAGAA CTGCATTGTT GTGGTGGACG CCGCGCCCTT    360
CAAGTTATGG TACGCGAAGC ACTACGGTAT CGACCTTGAG CCGCGAAGAG CAAGAAGACG    420
CTGCAGAGCA CGACGGAGAA GAAGAAGTCG AAGAAGACCT CACACGCCAT GACTGAGAAG    480
TACGACGTCA AGAAGGCCTC CGACGAGCTG AAGCGCAAGT GGATGCTCCG CCGCGAGAAC    540
CACAAGATTG AGAAGGCAGT TGCTGATCAG CTCAAGGAGG GCCGTCTGCT CGGCCGCATC    600
ACGAGCCGCC CTGGCCAGAC AGCCCGCGCC GATGGTGCAC TGCTGGAGGG CGCCGAACTG    660
CAGTTCTATC TGAAGAAGCT CGAGAAGAAG AAGCGGTAGA GAAGGATGTT CGGGAGACGG    720
GAGGAGGCGC CACCACCACC ACTCATGGTG ATGCACCCAC TACCTACTTT GTTTTCATTT    780
TTTGTTTTAC CTCTAATTTT TTAGGCCAGA GGGGGGGAAA AAAAAAAAAA AAAAA         835 
           
           
             
               555 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             20
GGCACGAGAA AAAAGAAAAC AAACAAATAA AATCAAAAAC AGTAAATCCA TCACTTCAAC     60
AATGAGCATT GAGAGCGCCT TTTACGCCTT TGCCTCCTTT GGTGGTGCGC CCACGAAAGA    120
GATGGACAAT GCTCACTTCT CCAAGATGCT GAAGGAGACG AAGGTCATTG GAAAGCAATT    180
CACCAGCACC GACGCCGATC TTCTCTTCAA CAAAGTGAAG GCAAAGGGAG CCCGCAAAAT    240
TACATTGTCG GATTTTGTTG ACAAGGCTGT TCCTGAGATT GCATCAAAGT TAAAGAAGTC    300
CGCGGAGGAA TTGATCGCAG ATATTTCAAG TTGCTCTCCC GAGGCACGCG CAACCAAGGC    360
CGATGCAGTT AAGTTCCACG ACGATAAGAA CATGTACACT GGTGTCTACA AGGCCGGCGG    420
GCCAACAAAC GTGGATCGCA ACTCCGGCTC CCTTTCAGGT GTCGTGGATC GCCGTGTGGC    480
GCAGACTGAC GTTCGTGGCA CGACTGCTTC CCAGAAGTAA AGAGGGAAAC GAAATGGAAA    540
AAAAAAAAAA AAAAA                                                     555 
           
           
             
               936 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             21
GGCACGAGAG CTCTCTTCGT CAGTCATGAC GCTCGGGAAG AACAAGCGCA TCAGCAAGGG     60
CGGCAAGCGC GGCAAGAAGA AGACCCAGGA GACGATGAGC CGCAAGGAGT GGTACGATGT    120
GGTTGCCCCC AAGAACTTTG AGGTGCGCCA GTTTGGCAAG ACCATCTGCA ACAAGACCCA    180
GGGCACAAAG ATCGCGGCGG ACTACCTGCG CGGGCGCGTG TACGAAAGCA ACCTTGCGGA    240
TCTGAACAAG ACGCAAGGCG ACGACGACGC CTACCGCAAG GTGAAGTTTG TTGTGCAGGA    300
GGTGCAGGGC CGCAACCTGC TTACGCAGTT CCACAGCATG GAAATGACAT CTGACCGCGT    360
GTACTTTTTG CTGCGCAAGT GGTGCACGAC GATCGAGGCG GCAGTGGAGA CGAAGACTGC    420
GGACGGCTAC ACCCTGCGCC TCTTCGTGAT TGCCTTCACG AAGAAGCAGA GCAACCAGCT    480
GTCGAAGAAC TGCTATGCCA AGACGCGCCT GGTGAAGTGG GTGCGCCATC GCATCACGAA    540
CCTCATCCGC CAGCGCCTGT CGAAGGTGAA CATCAACGAG GCGGTGACGC TGCTGACACG    600
CAACATCCTG CGCGATCGTC TGGCAAAGCG CTGCAACCCC ATCGTGCCGC TGCGCGATCT    660
CCGCATCCGC AAGGTGAAGG TGGTCCGCAC CCCCCGGTTT TGACGCCCAG GCGCTTCTGA    720
ATGCACACGG CGAGATCCCC GCCTCGGCTG AGGGTGAGGC ACGCGTCGTC GAGGAAGCCC    780
AAGAGGCTCC CGCCGCTGAA GCCACAGCCT AAGCCTTCCA TGTGGAGGAA GGATGTGTGA    840
TGTGAAAGCT CTTTGTTCTT TTTTCTTTCT ATTTTGAAAC GGTGATTCCG CATATATATA    900
TTAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAA                              936 
           
           
             
               581 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               unknown 
             
             22
GTACTATATT GTTGCTATTA ACACACTGTT AGGAACGCGA AACCATGCAG ATCTTCGTGA     60
AGACACTGAC GGGCAAGACG ATCGCGCTCG AGGTGGAATC CAGCGACACC ATTGAGAACG    120
TGAAGGCGAA GATCCAGGAC AAGGAGGGCA TTCCGCCGGA CCAGCAGCGC CTGATCTTCG    180
CTGGCAAGCA GCTGGAGGAC GGCCGCACGC TCGCAGACTA CAACATCCAG AAGGAGTCCA    240
CGCTGCACCT TGTGCTGCGC CTGCGCGGTG GTGTGATGGA GCCGACACTT GAGGCCCTGG    300
CGAAGAAGTA CAACTGGGAG AAGAAGGTAT GCCGCCGCTG CTACGCCCGT CTGCCGGTGC    360
GTGCGTCCAA CTGCCGCAAG AAGGCATGTG GCCACTGCTC CAACCTCCGC ATGAAGAAGA    420
AGCTGCGGTA GTCTGCGATG CTGTGGACCG ACGCATTGAA ATACACACCG TCTTCGGCGT    480
TCCTTTTTTT TATATGTCTT TTTTTTTATT GAGAAGATGT CTTGTTTGTT GTTGTTTTTT    540
TTTCAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA A                        581 
           
           
             
               30 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             23
Leu Pro Pro Leu Leu Pro Ser Ser Asp Val Pro Glu Gly Met Glu Leu
1               5                   10                  15
Pro Pro Leu Leu Pro Ser Ser Asp Ile Pro Glu Gly Met Glu
            20                  25                  30 
           
           
             
               90 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             24
Gly Cys Leu Leu Cys Phe Leu Pro Arg Thr Cys Pro Lys Ala Trp Ser
1               5                   10                  15
Cys Leu Leu Cys Phe Leu Pro Arg Thr Tyr Pro Lys Ala Trp Ser Cys
            20                  25                  30
His Leu Cys Phe Leu Pro Arg Thr Tyr Pro Arg Ala Trp Ser Cys His
        35                  40                  45
Leu Cys Phe Leu Pro Arg Thr Cys Pro Lys Ala Trp Ser Cys His Leu
    50                  55                  60
Cys Phe Leu Pro Arg Thr Tyr Pro Arg Ala Trp Ser Cys His Leu Cys
65                  70                  75                  80
Phe Leu Pro Arg Thr Tyr Pro Arg Val Trp
                85                  90 
           
           
             
               90 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             25
Ala Ala Ser Ser Ala Ser Phe Leu Gly Arg Ala Arg Arg His Gly Ala
1               5                   10                  15
Ala Ser Ser Ala Ser Phe Leu Gly His Thr Arg Arg His Gly Ala Ala
            20                  25                  30
Thr Ser Ala Ser Phe Leu Gly Arg Thr Arg Gly His Gly Ala Ala Thr
        35                  40                  45
Ser Ala Ser Phe Leu Gly Arg Ala Arg Arg His Gly Ala Ala Thr Ser
    50                  55                  60
Ala Ser Phe Leu Gly Arg Thr Arg Gly His Gly Ala Ala Thr Ser Ala
65                  70                  75                  80
Ser Phe Leu Gly Arg Thr Arg Gly His Gly
                85                  90 
           
           
             
               40 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             26
Ser Val Pro Gly Lys Arg Leu Arg Asn Ser His Gly Lys Ser Leu Arg
1               5                   10                  15
Asn Val His Gly Lys Arg Pro Lys Asn Glu His Gly Lys Arg Leu Arg
            20                  25                  30
Ser Val Pro Asn Glu Arg Leu Arg
        35                  40 
           
           
             
               40 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             27
Glu Ala Glu Glu Leu Ala Arg Gln Glu Ser Glu Glu Arg Ala Arg Gln
1               5                   10                  15
Glu Ala Glu Glu Arg Ala Trp Gln Glu Ala Glu Glu Arg Ala Gln Arg
            20                  25                  30
Glu Ala Glu Glu Arg Ala Gln Arg
        35                  40 
           
           
             
               56 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             28
Ser Trp Gln Ser Gln Ser His Gln Gln Gln Val Pro Thr Cys Ala Arg
1               5                   10                  15
Gln Ser Arg Ser His Gln Gln Gln Ala Pro Lys Trp Ser Trp Gln Ser
            20                  25                  30
Gln Ser His Gln Gln Gln Val Pro Thr Cys Ala Arg Gln Ser Arg Ser
        35                  40                  45
His Gln Gln Gln Val Pro Thr Trp
    50                  55 
           
           
             
               56 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             29
Gly Arg Gly Arg Ala Lys Ala Thr Asn Ser Arg Cys Arg Arg Val Arg
1               5                   10                  15
Gly Arg Ala Glu Ala Thr Ser Ser Arg Arg Arg Ser Gly Arg Gly Arg
            20                  25                  30
Ala Lys Ala Thr Ser Ser Arg Cys Arg Pro Val Arg Gly Arg Ala Glu
        35                  40                  45
Ala Thr Asn Ser Arg Cys Arg Arg
    50                  55 
           
           
             
               56 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             30
Val Val Ala Glu Pro Lys Pro Pro Thr Ala Gly Ala Asp Val Cys Ala
1               5                   10                  15
Ala Glu Pro Lys Pro Pro Ala Ala Gly Ala Glu Val Val Val Ala Glu
            20                  25                  30
Pro Lys Pro Pro Ala Ala Gly Ala Asp Val Cys Ala Ala Glu Pro Lys
        35                  40                  45
Pro Pro Thr Ala Gly Ala Asp Val
    50                  55 
           
           
             
               7 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             31
Pro Pro Ala Lys Ala Ala Ala
1               5 
           
           
             
               151 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             32
Val Leu Gln Lys Glu Arg Asp Glu Ala Val Ala Glu Asn Ala Gln Leu
1               5                   10                  15
Gln Lys Glu Arg Asp Asp Ala Val Ala Glu Asn Ala Gln Leu Gln Lys
            20                  25                  30
Glu Arg Asp Asp Ala Val Ala Glu Asn Ala Gln Leu Gln Lys Glu Arg
        35                  40                  45
Asp Asp Ala Val Ala Glu Asn Ala Gln Leu Gln Lys Glu Arg Asp Asp
    50                  55                  60
Ala Val Ala Glu Asn Ala Gln Leu Gln Lys Glu Arg Asp Glu Ala Val
65                  70                  75                  80
Ala Glu Asn Ala Gln Leu Gln Arg Glu Arg Asp Asp Ala Val Ala Glu
                85                  90                  95
Asp Ala Gln Leu Gln Lys Glu Arg Asp Glu Ala Val Ala Glu Asn Ala
            100                 105                 110
Gln Leu Gln Arg Glu Arg Asp Glu Ala Val Ala Glu Asn Ala Gln Leu
        115                 120                 125
Gln Lys Glu Arg Asp Asp Val Val Ala Glu Asn Ala Gln Leu Gln Lys
    130                 135                 140
Glu Arg Asp Asp Ala Val Ala
145                 150 
           
           
             
               140 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             33
Cys Arg Arg Arg Gly Met Lys Pro Trp Arg Arg Met Pro Ser Cys Arg
1               5                   10                  15
Arg Arg Gly Met Thr Pro Trp Arg Arg Met Pro Ser Cys Arg Arg Arg
            20                  25                  30
Gly Met Thr Pro Trp Arg Arg Met Pro Ser Cys Arg Arg Arg Gly Met
        35                  40                  45
Thr Pro Trp Arg Arg Met Pro Ser Cys Arg Arg Arg Gly Met Thr Pro
    50                  55                  60
Trp Arg Arg Met Pro Ser Cys Arg Arg Arg Gly Thr Lys Pro Trp Arg
65                  70                  75                  80
Arg Met Pro Ser Cys Arg Gly Arg Gly Met Thr Pro Trp Arg Arg Met
                85                  90                  95
Pro Ser Cys Arg Arg Arg Gly Met Lys Pro Trp Arg Arg Met Pro Ser
            100                 105                 110
Cys Arg Gly Arg Gly Met Lys Pro Trp Arg Arg Met Pro Ser Cys Arg
        115                 120                 125
Arg Arg Gly Met Thr Ser Trp Arg Arg Met Pro Ser
    130                 135                 140 
           
           
             
               60 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             34
Gly Tyr Val Arg Gly Arg Lys Gln Arg Trp Gln Leu His Ala Phe Gly
1               5                   10                  15
Tyr Val Arg Gly Arg Lys Gln Arg Trp Gln Leu His Ala Phe Gly Tyr
            20                  25                  30
Val Arg Gly Arg Lys Gln Arg Arg Gln Leu His Ala Cys Gly Tyr Val
        35                  40                  45
Arg Gly Arg Lys Gln Arg Trp Gln Leu His Ala Cys
    50                  55                  60 
           
           
             
               60 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             35
Gly Thr Ser Glu Glu Gly Ser Arg Gly Gly Ser Ser Met Pro Ser Gly
1               5                   10                  15
Thr Ser Glu Glu Gly Ser Arg Gly Gly Ser Ser Met Pro Ser Gly Thr
            20                  25                  30
Ser Glu Glu Gly Ser Arg Gly Gly Ser Ser Met Pro Ala Gly Thr Ser
        35                  40                  45
Glu Glu Gly Ser Arg Gly Gly Ser Ser Met Pro Ala
    50                  55                  60 
           
           
             
               60 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             36
Val Arg Pro Arg Lys Glu Ala Glu Val Ala Ala Pro Cys Leu Arg Val
1               5                   10                  15
Arg Pro Arg Lys Glu Ala Glu Val Ala Ala Pro Cys Leu Arg Val Arg
            20                  25                  30
Pro Arg Lys Glu Ala Glu Glu Ala Ala Pro Cys Leu Arg Val Arg Pro
        35                  40                  45
Arg Lys Glu Ala Glu Val Ala Ala Pro Cys Leu Arg
    50                  55                  60 
           
           
             
               639 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             37
Asp Ala Ser Val Val Asp Leu Gly Gly Glu Ala His Gly Thr His Tyr
1               5                   10                  15
Ala Phe Leu Pro Asp Val Ile Lys Gly Ile Ala Gln Glu Glu Leu Tyr
            20                  25                  30
Leu Glu Asp Asp Ala Tyr Phe Gln Glu Leu Leu Ala Arg Tyr Lys Glu
        35                  40                  45
Leu Val Pro Val Gly Ala Glu Pro Thr Glu Pro Arg Ala Lys Gln Leu
    50                  55                  60
Arg Glu Gln Met Arg Ile Arg Ala Gly Gln Leu Ala Val Asp Thr Arg
65                  70                  75                  80
Lys Leu His Ala Ala Glu Glu Arg Ala Ala Ser Arg Met Ala Thr Leu
                85                  90                  95
Tyr Pro Phe Val Gly Ser Ala Pro Leu Gly Val Ala Leu Trp Asn Ile
            100                 105                 110
Pro Val Glu Ala Asp Glu Glu Phe Cys Ala Leu Leu Leu Lys Arg Glu
        115                 120                 125
Glu Ala Leu Ala Gly Lys Ser Gly Ser Val His Glu Val Glu Ser Ala
    130                 135                 140
Leu Ser Ala Arg Ala Glu Ala Met Ala Lys Ala Val Leu Glu Glu Glu
145                 150                 155                 160
Glu Ala Leu Ala Ala Ala Phe Pro Phe Leu Gly Arg Ser Val Lys Gly
                165                 170                 175
Ala Pro Leu Arg Glu Leu Ala Leu Met Ser Asp Pro Asn Phe Ala Glu
            180                 185                 190
Leu Ala Thr Arg His Ala Gln Glu Ala Thr Ser Gly Asp Ala Ala Gly
        195                 200                 205
Ile Leu Arg Leu Glu Gln Glu Leu Arg Asp Gln Ala Cys Arg Ile Ala
    210                 215                 220
Arg Glu Val Arg Val Ala Arg Arg Leu Asp Ala Xaa Arg Asn Glu Asp
225                 230                 235                 240
Leu His Glu Arg Tyr Pro Phe Leu Pro Glu Glu Pro Val Arg Gly Ile
                245                 250                 255
Leu Leu Gly Ala Val Arg Pro Val Gln Gln Pro Ala Phe Arg Glu Leu
            260                 265                 270
Ser Asn Lys Leu Asp Glu Gln Arg Arg Asp Pro Thr Arg Asn Ala Ala
        275                 280                 285
Ala Ile Arg Thr Thr Glu Glu Gln Met Thr Ala Leu Val Val Arg Leu
    290                 295                 300
Ala Glu Glu Arg Ala Glu Ala Thr Glu Arg Ala His Glu Gln Tyr Pro
305                 310                 315                 320
Phe Leu Pro Arg Arg Val Leu Gly Val Arg Leu Gly Asp Ile Ser Leu
                325                 330                 335
Gln Glu Asp Asp Val Leu Ser Gln Leu Ala Arg Arg Arg Val Arg Gln
            340                 345                 350
Leu Arg Asn Ser Lys Thr Ala Ile Asp Ala His Ala Thr Glu Glu Glu
        355                 360                 365
Met Ile Arg Arg Ala Glu Glu Leu Ala Arg Asn Val Lys Leu Val Asp
    370                 375                 380
Ala Tyr Arg Gly Asn Gly Asn Glu Tyr Val Arg Ala Cys Asn Pro Phe
385                 390                 395                 400
Leu Val Tyr Glu Asp Arg Lys Cys Val Leu Leu Ser Glu Leu Pro Leu
                405                 410                 415
Ala Gly Gly Asp Val Tyr Gln Gly Leu Phe Arg Asp Tyr Leu Thr Ala
            420                 425                 430
Leu Glu Asp Ala Glu Ala Asn Ala Pro Arg Ile Ala Glu Leu Glu Asn
        435                 440                 445
Ala Leu Arg Ser Arg Ala Asp Glu Leu Ala Leu Glu Val Cys Glu Arg
    450                 455                 460
Asp Ala Arg Leu Leu His Tyr Ser Phe Leu Ser Ala Gln Asp Val Pro
465                 470                 475                 480
Gly Trp Ser Glu Ala Leu Leu His Asp Ala Glu Phe Gln Gln Leu Arg
                485                 490                 495
Glu Arg Tyr Glu Glu Leu Ser Lys Asp Pro Gln Gly Asn Ala Glu Ala
            500                 505                 510
Leu Arg Glu Leu Glu Asp Ala Met Glu Ala Arg Ser Arg Ala Ile Ala
        515                 520                 525
Glu Ala Leu Arg Thr Ala Glu Xaa Thr Asn Xaa Thr Glu Gln Ala Arg
    530                 535                 540
Leu Lys Thr Pro Ser Gln Ala Gly Ser Gly Val Ser Ala Gly Asp Arg
545                 550                 555                 560
Met His Gly Ser Glu His Ala Asp Leu Ala His Glu Gly Gly Ser Thr
                565                 570                 575
Ala Gly Gly Thr Met Arg Gly Ala Glu Ser Val Ser Lys Ser Ser Gly
            580                 585                 590
Lys His Ser Xaa Arg Ser Val Ser His Ala Ser Val Val Asp Leu Gly
        595                 600                 605
Gly Glu Ala His Gly Thr His Tyr Ala Phe Leu Pro Asp Val Ile Lys
    610                 615                 620
Gly Ile Ala Gln Glu Glu Leu Tyr Leu Glu Asp Asp Ala Tyr Phe
625                 630                 635 
           
           
             
               231 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             38
Ala Arg Ala Val Leu Tyr Cys Arg Arg Ala Ala Met Gly Ile Val Arg
1               5                   10                  15
Ser Arg Leu His Lys Arg Lys Ile Thr Gly Gly Lys Thr Lys Ile His
            20                  25                  30
Arg Lys Arg Met Lys Ala Glu Leu Gly Arg Leu Pro Ala His Thr Lys
        35                  40                  45
Leu Gly Ala Arg Arg Val Ser Pro Val Arg Ala Arg Gly Gly Asn Phe
    50                  55                  60
Lys Leu Arg Gly Leu Arg Leu Asp Thr Gly Asn Phe Ala Trp Ser Thr
65                  70                  75                  80
Glu Ala Ile Ala Gln Arg Ala Arg Ile Leu Asp Val Val Tyr Asn Ala
                85                  90                  95
Thr Ser Asn Glu Leu Val Arg Thr Lys Thr Leu Val Lys Asn Cys Ile
            100                 105                 110
Val Val Val Asp Ala Ala Pro Phe Lys Leu Trp Tyr Ala Lys His Tyr
        115                 120                 125
Gly Ile Asp Leu Asp Ala Ala Lys Ser Lys Lys Thr Leu Gln Ser Thr
    130                 135                 140
Thr Glu Lys Lys Lys Ser Lys Lys Thr Ser His Ala Met Thr Glu Lys
145                 150                 155                 160
Tyr Asp Val Lys Lys Ala Ser Asp Glu Leu Lys Arg Lys Trp Met Leu
                165                 170                 175
Arg Arg Glu Asn His Lys Ile Glu Lys Ala Val Ala Asp Gln Leu Lys
            180                 185                 190
Glu Gly Arg Leu Leu Ala Arg Ile Thr Ser Arg Pro Gly Thr Ala Arg
        195                 200                 205
Ala Asp Gly Ala Leu Leu Glu Gly Ala Glu Leu Gln Phe Tyr Leu Lys
    210                 215                 220
Lys Leu Glu Lys Lys Lys Arg
225                 230 
           
           
             
               172 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             39
Ala Arg Glu Lys Arg Lys Gln Thr Asn Lys Ile Lys Asn Ser Lys Ser
1               5                   10                  15
Ile Thr Ser Thr Met Ser Glu Glu Ser Ala Phe Tyr Ala Phe Ala Ser
            20                  25                  30
Phe Gly Gly Ala Pro Thr Lys Glu Met Asp Asn Ala His Phe Ser Lys
        35                  40                  45
Met Leu Lys Glu Thr Lys Val Ile Gly Lys Gln Phe Thr Ser Thr Asp
    50                  55                  60
Ala Asp Leu Leu Phe Asn Lys Val Lys Ala Lys Gly Ala Arg Lys Ile
65                  70                  75                  80
Thr Leu Ser Asp Phe Val Asp Lys Ala Val Pro Glu Ile Ala Ser Lys
                85                  90                  95
Leu Lys Lys Ser Ala Glu Glu Leu Ile Ala Asp Ile Ser Ser Cys Ser
            100                 105                 110
Pro Glu Ala Arg Ala Thr Lys Ala Asp Ala Val Lys Phe His Asp Asp
        115                 120                 125
Lys Asn Met Tyr Thr Gly Val Tyr Lys Ala Gly Gly Pro Thr Asn Val
    130                 135                 140
Asp Arg Asn Ser Gly Ser Leu Ser Gly Val Val Asp Arg Arg Val Ala
145                 150                 155                 160
Gln Thr Asp Val Arg Gly Thr Thr Ala Ser Gln Lys
                165                 170 
           
           
             
               233 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             40
Ala Arg Glu Leu Ser Ser Ser Val Met Thr Leu Gly Lys Asn Lys Arg
1               5                   10                  15
Ile Ser Lys Gly Gly Lys Arg Gly Lys Lys Lys Thr Gln Glu Thr Met
            20                  25                  30
Ser Arg Lys Glu Trp Tyr Asp Val Val Ala Pro Lys Asn Phe Glu Val
        35                  40                  45
Arg Gln Phe Gly Lys Thr Ile Cys Asn Lys Thr Gln Gly Thr Lys Ile
    50                  55                  60
Ala Ala Asp Tyr Leu Arg Gly Arg Val Tyr Glu Ser Asn Leu Ala Asp
65                  70                  75                  80
Leu Asn Lys Thr Gln Gly Asp Asp Asp Ala Tyr Arg Lys Val Lys Phe
                85                  90                  95
Val Val Gln Glu Val Gln Gly Arg Asn Leu Leu Thr Gln Phe His Ser
            100                 105                 110
Met Glu Met Thr Ser Asp Arg Val Tyr Phe Leu Leu Arg Lys Trp Cys
        115                 120                 125
Thr Thr Ile Glu Ala Ala Val Glu Thr Lys Thr Ala Asp Gly Tyr Thr
    130                 135                 140
Leu Arg Leu Phe Val Ile Ala Phe Thr Lys Lys Gln Ser Asn Gln Leu
145                 150                 155                 160
Ser Lys Asn Cys Tyr Ala Lys Thr Arg Leu Val Lys Trp Val Arg His
                165                 170                 175
Arg Ile Thr Asn Leu Ile Arg Gln Arg Leu Ser Lys Val Asn Ile Asn
            180                 185                 190
Glu Ala Val Thr Leu Leu Thr Arg Asn Ile Leu Arg Asp Arg Leu Ala
        195                 200                 205
Lys Arg Cys Asn Pro Ile Val Pro Leu Arg Asp Leu Arg Ile Arg Lys
    210                 215                 220
Val Lys Val Val Arg Thr Pro Arg Phe
225                 230 
           
           
             
               128 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             41
Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Ala Leu Glu
1               5                   10                  15
Val Glu Ser Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp
            20                  25                  30
Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys
        35                  40                  45
Gln Leu Glu Asp Gly Arg Thr Leu Ala Asp Tyr Asn Ile Gln Lys Glu
    50                  55                  60
Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Val Met Glu Pro
65                  70                  75                  80
Thr Leu Glu Ala Leu Ala Lys Lys Tyr Asn Trp Glu Lys Lys Val Cys
                85                  90                  95
Arg Arg Cys Tyr Ala Arg Leu Pro Val Arg Ala Ser Asn Cys Arg Lys
            100                 105                 110
Lys Ala Cys Gly His Cys Ser Asn Leu Arg Met Lys Lys Lys Leu Arg
        115                 120                 125 
           
           
             
               145 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             42
Arg Leu Pro Pro Leu Leu Pro Ser Ser Asp Val Pro Glu Gly Met Glu
1               5                   10                  15
Leu Pro Pro Leu Leu Pro Ser Ser Asp Ile Pro Glu Gly Met Glu Leu
            20                  25                  30
Pro Pro Leu Leu Pro Ser Ser Asp Val Pro Ala Gly Met Glu Leu Thr
        35                  40                  45
Pro Leu Leu Pro Ser Ser Asp Val Pro Glu Gly Met Glu Leu Pro Pro
    50                  55                  60
Leu Leu Pro Ser Ser Asp Val Pro Ala Gly Met Glu Leu Pro Pro Leu
65                  70                  75                  80
Xaa Pro Ser Ser Asp Val Pro Ala Gly Met Glu Leu Pro Pro Leu Leu
                85                  90                  95
Pro Ser Ser Asp Val Pro Ala Xaa Ile Glu Leu Pro Pro Leu Ile Ser
            100                 105                 110
Xaa Leu Gly Arg Thr Xaa Arg Xaa Gly Asp Xaa Ser Ser Xaa Ser Cys
        115                 120                 125
Leu Gly Arg Xaa Xaa Arg Xaa Arg Xaa Ala Pro Leu Xaa Pro Xaa Ser
    130                 135                 140
Glu
145 
           
           
             
               186 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             43
Glu Lys Glu Arg Arg Phe Pro Thr Lys Thr Ala Arg Ala Asp Pro Thr
1               5                   10                  15
Thr Thr Lys Gln Leu Ile Ile Arg Ala Leu Gln Asn Ile Ser Leu Ala
            20                  25                  30
Phe Gly Ile Glu Pro Ser Ser Thr Val Lys Tyr Ala Glu Ser Thr Gln
        35                  40                  45
Glu Glu Asn Gly Lys Arg Ser Gln Ser Glu Ala Glu Glu Arg Ala Arg
    50                  55                  60
Arg Glu Ala Glu Glu Arg Ala Arg Arg Glu Ala Glu Glu Arg Ala Gln
65                  70                  75                  80
Arg Glu Ala Glu Glu Arg Ala Gln Arg Glu Ala Glu Glu Arg Ala Arg
                85                  90                  95
Arg Glu Ala Glu Lys Arg Ala Arg Arg Glu Ala Lys Glu Arg Ala Trp
            100                 105                 110
Gln Glu Ala Glu Glu Arg Ala Gln Arg Glu Ala Glu Glu Arg Ala Arg
        115                 120                 125
Arg Glu Ala Glu Glu Arg Ala Arg Arg Glu Val Glu Glu Arg Ala Arg
    130                 135                 140
Gln Glu Ala Glu Glu Leu Ala Arg Gln Glu Ser Glu Glu Arg Ala Arg
145                 150                 155                 160
Gln Glu Ala Glu Glu Arg Ala Trp Gln Glu Ala Glu Glu Arg Ala Gln
                165                 170                 175
Arg Glu Ala Glu Glu Arg Ala Gln Arg Ala
            180                 185 
           
           
             
               106 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             44
Gly Arg Gly Arg Ala Lys Ala Thr Asn Ser Arg Cys Arg Arg Val Arg
1               5                   10                  15
Gly Arg Ala Glu Ala Thr Ser Ser Arg Arg Arg Ser Gly Arg Gly Arg
            20                  25                  30
Ala Lys Ala Thr Ser Ser Arg Cys Arg Arg Val Arg Gly Arg Val Glu
        35                  40                  45
Ala Thr Asn Ser Arg Cys Arg Arg Gly Arg Gly Arg Ala Lys Val Thr
    50                  55                  60
Ser Ser Arg Xaa Arg Arg Val Xaa Gly Arg Xaa Xaa Xaa Thr Ser Xaa
65                  70                  75                  80
Arg Xaa Arg Arg Xaa Arg Gly Arg Xaa Xaa Val Thr Ser Arg Arg Xaa
                85                  90                  95
Arg Arg Xaa Xaa Gly Arg Gly Asp Val Thr
            100                 105 
           
           
             
               141 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             45
Ser Ile Pro Val Glu Ile Asp Ile Arg Asn Gln Asp Phe Ser Phe Leu
1               5                   10                  15
Asp Pro Ala Pro Glu Gly Ile Pro Ile Gln Asp Ile His Leu Met Gly
            20                  25                  30
Asp Ser Ala Phe Ala Ala Ser Ala Arg Glu Arg Met Lys Leu Lys Arg
        35                  40                  45
Asn Pro Val Ala Asn Ala Ser Lys Ile Ser Ala Leu Glu Glu Glu Met
    50                  55                  60
Asp Gln Arg Ala His Val Leu Ala Lys Gln Val Arg Asp Lys Glu Arg
65                  70                  75                  80
Thr Phe Leu Asp Pro Glu Pro Glu Gly Val Pro Leu Glu Leu Leu Ser
                85                  90                  95
Leu Asn Glu Asn Glu Ala Ser Gln Glu Leu Glu Arg Glu Leu Arg Ala
            100                 105                 110
Leu Asn Arg Lys Pro Arg Lys Asp Ala Lys Ala Ile Val Ala Leu Glu
        115                 120                 125
Asp Asp Val Arg Asp Glu His Thr Cys Leu Pro Arg Ser
    130                 135                 140 
           
           
             
               27 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             46
Arg Lys Met Ser Gly Thr Ser Leu Leu Ala Pro Gln Pro Glu Gly Val
1               5                   10                  15
Pro Val Ser Glu Leu Ser Leu Asp Leu Asp Glu
            20                  25 
           
           
             
               117 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             47
Leu Leu Ala Leu Leu Gln Gly Leu Val Gln Leu Arg Thr Gln Ile His
1               5                   10                  15
Gly Val Arg Pro Ala Leu Leu Pro Glu Ser Gly Gln Phe Leu Gly Gly
            20                  25                  30
Ser Leu Gln Leu Ala Met His Leu Leu Ala Leu Leu Gln Gly Leu Val
        35                  40                  45
Gln Leu Arg Thr Gln Ile His Gly Val Arg Pro Ala Leu Leu Pro Glu
    50                  55                  60
Ser Gly Gln Phe Leu Gly Gly Ser Leu Gln Leu Ala Met His Leu Leu
65                  70                  75                  80
Ala Leu Leu Gln Gly Leu Val Gln Leu Arg Thr Gln Ile His Gly Val
                85                  90                  95
Arg Pro Ala Leu Leu Pro Glu Ser Gly Gln Phe Leu Gly Gly Ser Leu
            100                 105                 110
Gln Leu Ala Thr His
        115 
           
           
             
               117 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             48
Ser Ser Arg Cys Cys Lys Ala Ser Ser Ser Cys Ala Arg Arg Phe Thr
1               5                   10                  15
Val Ser Ala Pro Leu Cys Ser Arg Arg Ala Ala Ser Ser Ser Val Val
            20                  25                  30
Arg Phe Ser Ser Arg Cys Thr Ser Ser Arg Cys Cys Lys Ala Ser Ser
        35                  40                  45
Ser Cys Ala Arg Arg Phe Thr Val Ser Ala Pro Leu Cys Ser Arg Arg
    50                  55                  60
Ala Gly Ser Ser Ser Val Val Arg Phe Ser Ser Arg Cys Thr Ser Ser
65                  70                  75                  80
Arg Cys Cys Lys Ala Ser Ser Ser Cys Ala Arg Arg Phe Thr Val Ser
                85                  90                  95
Ala Pro Leu Cys Ser Arg Arg Ala Gly Ser Ser Ser Val Val Arg Phe
            100                 105                 110
Ser Ser Arg Arg Thr
        115 
           
           
             
               117 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             49
Pro Pro Arg Ala Ala Ala Arg Pro Arg Pro Ala Ala His Ala Asp Ser
1               5                   10                  15
Arg Cys Pro Pro Arg Ser Ala Pro Gly Glu Arg Pro Val Pro Arg Trp
            20                  25                  30
Phe Ala Ser Ala Arg Asp Ala Pro Pro Arg Ala Ala Ala Arg Pro Arg
        35                  40                  45
Pro Ala Ala His Ala Asp Ser Arg Cys Pro Pro Arg Ser Ala Pro Gly
    50                  55                  60
Glu Arg Ala Val Pro Arg Trp Phe Ala Ser Ala Arg Asp Ala Pro Pro
65                  70                  75                  80
Arg Ala Ala Ala Arg Pro Arg Pro Ala Ala His Ala Asp Ser Arg Cys
                85                  90                  95
Pro Pro Arg Ser Ala Pro Gly Glu Arg Ala Val Pro Arg Trp Phe Ala
            100                 105                 110
Ser Ala Arg Asp Ala
        115 
           
           
             
               207 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             50
Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala
1               5                   10                  15
Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu
            20                  25                  30
Pro Lys Pro Ala Glu Pro Lys Ser Ala Gly Pro Lys Pro Ala Glu Pro
        35                  40                  45
Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys
    50                  55                  60
Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser
65                  70                  75                  80
Ala Glu Pro Lys Pro Ala Glu Ser Lys Ser Ala Glu Pro Lys Pro Ala
                85                  90                  95
Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Ser Lys Ser Ala Glu
            100                 105                 110
Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro
        115                 120                 125
Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys
    130                 135                 140
Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Ser Lys Ser
145                 150                 155                 160
Ala Gly Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala
                165                 170                 175
Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu
            180                 185                 190
Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu
        195                 200                 205 
           
           
             
               263 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             51
Arg Arg Gly Tyr Pro Arg Ser Arg Met Pro Ser Lys Glu Leu Trp Met
1               5                   10                  15
Arg Arg Leu Arg Ile Leu Arg Arg Leu Leu Arg Lys Tyr Arg Glu Glu
            20                  25                  30
Lys Lys Ile Asp Arg His Ile Tyr Arg Glu Leu Tyr Val Lys Ala Lys
        35                  40                  45
Gly Asn Val Phe Arg Asn Lys Arg Asn Leu Met Glu His Ile His Lys
    50                  55                  60
Val Lys Asn Glu Lys Lys Lys Glu Arg Gln Leu Ala Glu Gln Leu Ala
65                  70                  75                  80
Ala Asn Ala Xaa Lys Asp Glu Gln His Arg His Lys Ala Arg Lys Gln
                85                  90                  95
Glu Leu Arg Lys Arg Glu Lys Asp Arg Glu Arg Ala Arg Arg Glu Asp
            100                 105                 110
Ala Ala Ala Ala Ala Ala Ala Lys Gln Lys Ala Ala Ala Lys Lys Ala
        115                 120                 125
Ala Ala Pro Ser Gly Lys Lys Ser Ala Lys Ala Ala Ile Ala Pro Ala
    130                 135                 140
Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala
145                 150                 155                 160
Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala
                165                 170                 175
Ala Pro Ala Lys Ala Ala Thr Ala Pro Ala Lys Ala Ala Ala Ala Pro
            180                 185                 190
Ala Lys Thr Ala Ala Ala Pro Ala Lys Ala Ala Ala Pro Ala Lys Ala
        195                 200                 205
Ala Ala Ala Pro Ala Lys Ala Ala Thr Ala Pro Ala Lys Ala Ala Ala
    210                 215                 220
Ala Pro Ala Lys Ala Ala Thr Ala Pro Ala Lys Ala Ala Thr Ala Pro
225                 230                 235                 240
Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Thr Ala Pro Val Gly
                245                 250                 255
Lys Lys Ala Gly Gly Lys Lys
            260 
           
           
             
               442 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             52
Asp Phe Ile Trp Tyr Lys Val Val Ala Leu Leu Val Val Ile Thr Ser
1               5                   10                  15
Asn Gly Asp Asp Val Ser Val Tyr Thr Ala Thr Ile Lys Glu Phe Tyr
            20                  25                  30
Arg Tyr Leu Trp Ile Phe Val Pro Val Ser Leu Phe Ser Ile Ile Ile
        35                  40                  45
Tyr Phe Val Ser Ile Phe Cys Phe Pro Ala Ser Tyr Gly Leu Phe Phe
    50                  55                  60
Ser Ser Phe Leu Lys Phe Gln Leu Leu Leu Asn His Lys His Pro Val
65                  70                  75                  80
Leu Gln Pro Pro His Gln Met Val Ser Leu Lys Leu Gln Ala Arg Leu
                85                  90                  95
Ala Ala Asp Ile Leu Arg Cys Gly Arg His Arg Val Trp Leu Asp Pro
            100                 105                 110
Asn Glu Ala Ser Glu Ile Ser Asn Ala Asn Ser Arg Lys Ser Val Arg
        115                 120                 125
Lys Leu Ile Lys Asp Gly Leu Ile Ile Arg Lys Pro Val Lys Val His
    130                 135                 140
Ser Arg Ser Arg Trp Arg His Met Lys Glu Ala Lys Ser Met Gly Arg
145                 150                 155                 160
His Glu Gly Ala Gly Arg Arg Glu Gly Thr Arg Glu Ala Arg Met Pro
                165                 170                 175
Ser Lys Glu Leu Trp Met Arg Arg Leu Arg Ile Leu Arg Arg Leu Leu
            180                 185                 190
Arg Lys Tyr Arg Glu Glu Lys Lys Ile Asp Arg His Ile Tyr Arg Glu
        195                 200                 205
Leu Tyr Val Lys Ala Lys Gly Asn Val Phe Arg Asn Lys Arg Asn Leu
    210                 215                 220
Met Glu His Ile His Lys Val Lys Asn Glu Lys Lys Lys Glu Arg Gln
225                 230                 235                 240
Leu Ala Glu Gln Leu Ala Ala Lys Arg Leu Lys Asp Glu Gln His Arg
                245                 250                 255
His Lys Ala Arg Lys Gln Glu Leu Arg Lys Arg Glu Lys Asp Arg Glu
            260                 265                 270
Arg Ala Arg Arg Glu Asp Ala Ala Ala Ala Ala Ala Ala Lys Gln Lys
        275                 280                 285
Ala Ala Ala Lys Lys Ala Ala Ala Pro Ser Gly Lys Lys Ser Ala Lys
    290                 295                 300
Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala
305                 310                 315                 320
Pro Pro Ala Lys Thr Ala Ala Ala Pro Ala Lys Ala Ala Ala Pro Ala
                325                 330                 335
Lys Ala Ala Ala Pro Pro Ala Lys Ala Ala Ala Pro Pro Ala Lys Thr
            340                 345                 350
Ala Ala Pro Pro Ala Lys Thr Ala Ala Pro Pro Ala Lys Ala Ala Ala
        355                 360                 365
Pro Pro Ala Lys Ala Ala Ala Pro Pro Ala Lys Ala Ala Ala Pro Pro
    370                 375                 380
Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys
385                 390                 395                 400
Ala Ala Ala Pro Pro Ala Lys Ala Ala Ala Pro Pro Ala Lys Ala Ala
                405                 410                 415
Ala Pro Pro Ala Lys Ala Ala Ala Pro Pro Ala Lys Ala Ala Ala Ala
            420                 425                 430
Pro Val Gly Lys Lys Ala Gly Gly Lys Lys
        435                 440 
           
           
             
               15 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             53
Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser
1               5                   10                  15 
           
           
             
               15 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             54
Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro
1               5                   10                  15 
           
           
             
               21 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             55
Lys Ala Ala Ile Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala
1               5                   10                  15
Ala Thr Ala Pro Ala
            20 
           
           
             
               21 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             56
Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala
1               5                   10                  15
Ala Ala Ala Pro Ala
            20 
           
           
             
               22 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             57
Gly Asp Lys Pro Ser Pro Phe Gly Gln Ala Ala Ala Gly Asp Lys Pro
1               5                   10                  15
Ser Pro Phe Gly Gln Ala
            20 
           
           
             
               21 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             58
Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Lys Ala
1               5                   10                  15
Ala Ala Ala Pro Ala
            20 
           
           
             
               21 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             59
Lys Ala Ala Thr Ala Pro Ala Lys Ala Ala Thr Ala Pro Ala Lys Ala
1               5                   10                  15
Ala Thr Ala Pro Ala
            20 
           
           
             
               21 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             60
Lys Ala Ala Ile Ala Pro Ala Lys Ala Ala Ile Ala Pro Ala Lys Ala
1               5                   10                  15
Ala Ile Ala Pro Ala
            20 
           
           
             
               14 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             61
Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala
1               5                   10 
           
           
             
               14 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             62
Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Thr Ala Pro Ala
1               5                   10 
           
           
             
               83 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             63
Gly Asp Lys Pro Ser Pro Phe Gly Gln Ala Ala Ala Gly Asp Lys Pro
1               5                   10                  15
Ser Pro Phe Gly Gln Ala Gly Cys Gly Ser Ser Met Pro Ser Gly Thr
            20                  25                  30
Ser Glu Glu Gly Ser Arg Gly Gly Ser Ser Met Pro Ala Gly Cys Gly
        35                  40                  45
Lys Ala Ala Ala Ala Pro Ala Lys Ala Ala Ala Ala Pro Ala Gly Cys
    50                  55                  60
Gly Ala Glu Pro Lys Ser Ala Glu Pro Lys Pro Ala Glu Pro Lys Ser
65                  70                  75                  80
Gly Cys Gly 
           
           
             
               21 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             64
Lys Thr Ala Ala Pro Pro Ala Lys Thr Ala Ala Pro Pro Ala Lys Thr
1               5                   10                  15
Ala Ala Pro Pro Ala
            20 
           
           
             
               618 amino acids 
               amino acid 
                 
               linear 
             
             
               unknown 
             
             65
Lys Ala Val Asp Pro Phe Gln Gly Thr Thr Pro Pro Pro Tyr Lys Trp
1               5                   10                  15
Gln Glu Met Thr Gly Ser Glu Ala Ala Ala Gly Ser Leu Cys Val Pro
            20                  25                  30
Ser Leu Ala Glu Val Ala Gly Gly Val Phe Ala Val Ala Glu Ala Gln
        35                  40                  45
Arg Ser Glu Arg Asp Glu Ala Cys Gly His Ala Ala Ile Ala Thr Thr
    50                  55                  60
His Ile Glu Thr Gly Gly Gly Gly Ser Lys Ala Ile Ser Ala Met Asp
65                  70                  75                  80
Ala Gly Val Phe Leu Val Glu Leu Val Asp Ala Ala Ser Gly Thr Ile
                85                  90                  95
Arg Thr Arg Glu Lys Met Gln Pro Thr Thr Ile Val Ser Gly Asp Thr
            100                 105                 110
Ile Tyr Met Ala Leu Gly Asp Tyr Glu Lys Lys Thr Ser Gly Gly Arg
        115                 120                 125
Ala Ala Asp Ala Asp Gly Trp Arg Leu Leu Leu Met Arg Gly Thr Leu
    130                 135                 140
Thr Glu Asp Gly Gly Gln Lys Lys Ile Met Trp Gly Asp Ile Arg Ala
145                 150                 155                 160
Val Asp Pro Val Ala Ile Gly Leu Thr Gln Phe Leu Lys Arg Val Ile
                165                 170                 175
Gly Gly Gly Gly Ser Gly Val Val Thr Lys Asn Gly Tyr Leu Val Leu
            180                 185                 190
Pro Met Gln Ala Val Glu Lys Asp Gly Arg Ser Val Val Leu Ser Met
        195                 200                 205
Arg Phe Asn Met Arg Ile Glu Ala Cys Glu Leu Ser Ser Gly Thr Thr
    210                 215                 220
Gly Ser Asn Cys Lys Glu Pro Ser Ile Ala Asn Leu Glu Gly Asn Leu
225                 230                 235                 240
Ile Leu Ile Thr Ser Cys Ala Ala Gly Tyr Tyr Glu Val Phe Arg Ser
                245                 250                 255
Leu Asp Ser Gly Thr Ser Trp Glu Met Ser Gly Arg Pro Ile Ser Arg
            260                 265                 270
Val Trp Gly Asn Ser Tyr Gly Arg Lys Gly Tyr Gly Val Arg Cys Gly
        275                 280                 285
Leu Thr Thr Val Thr Ile Glu Gly Arg Glu Val Leu Leu Val Thr Thr
    290                 295                 300
Pro Val Tyr Leu Glu Glu Lys Asn Gly Arg Gly Arg Leu His Leu Trp
305                 310                 315                 320
Val Thr Asp Gly Ala Arg Val His Asp Ala Gly Pro Ile Ser Asp Ala
                325                 330                 335
Ala Asp Asp Ala Ala Ala Ser Ser Leu Leu Tyr Ser Ser Gly Gly Asn
            340                 345                 350
Leu Ile Ser Leu Tyr Glu Asn Lys Ser Glu Gly Ser Tyr Gly Leu Val
        355                 360                 365
Ala Val His Val Thr Thr Gln Leu Glu Arg Ile Lys Thr Val Leu Lys
    370                 375                 380
Arg Trp Gln Glu Leu Asp Glu Ala Leu Arg Thr Cys Arg Ser Thr Ala
385                 390                 395                 400
Thr Ile Asp Pro Val Arg Arg Gly Met Cys Ile Arg Pro Ile Leu Thr
                405                 410                 415
Asp Gly Leu Val Gly Tyr Leu Ser Gly Leu Ser Thr Gly Ser Glu Trp
            420                 425                 430
Met Asp Glu Tyr Leu Cys Val Asn Ala Thr Val His Gly Thr Val Arg
        435                 440                 445
Gly Phe Ser Asn Gly Val Thr Phe Glu Gly Pro Gly Ala Gly Ala Gly
    450                 455                 460
Trp Pro Val Ala Arg Ser Gly Gln Asn Gln Pro Tyr His Phe Leu His
465                 470                 475                 480
Lys Thr Phe Thr Leu Val Val Met Ala Val Ile His Asp Arg Pro Lys
                485                 490                 495
Lys Arg Thr Pro Ile Pro Leu Ile Arg Val Val Met Asp Asp Asn Asp
            500                 505                 510
Lys Thr Val Leu Phe Gly Val Phe Tyr Thr His Asp Gly Arg Trp Met
        515                 520                 525
Thr Val Ile His Ser Gly Gly Arg Gln Ile Leu Ser Thr Gly Trp Asp
    530                 535                 540
Pro Glu Lys Pro Cys Gln Val Val Leu Arg His Asp Thr Gly His Trp
545                 550                 555                 560
Asp Phe Tyr Val Asn Ala Arg Lys Ala Tyr Phe Gly Thr Tyr Lys Gly
                565                 570                 575
Leu Phe Ser Lys Gln Thr Val Phe His Thr Ser Asn Ser Thr Gly Arg
            580                 585                 590
Val Gly Lys Leu Gln Ser Pro Ala Ile Cys His Ser Ser Thr Pro Val
        595                 600                 605
Cys Ile Thr Glu Asp Ser Ile Pro Ser Ile
    610                 615 
           
           
             
               39 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             66
GGGGACAAAC CGTCTCCGTT CCAGGCTGCT GCTGGTGAC                            39 
           
           
             
               49 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             67
GAGACGGTTT GTCACCAGCA GCAGCCTGGA ACGGAGACGG TTTGTCCCC                 49 
           
           
             
               40 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             68
AAACCGTCTC CGTTCGGTCA GGCTGCTGAA CCGAAATCTG                           40 
           
           
             
               40 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             69
TTCGGTTCAG CAGATTTCGG TTCAGCAGCC TGACCGAACG                           40 
           
           
             
               51 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             70
CTGAACCGAA ACCGGCTGAA CCGAAAAGCG CTCTAGATGC ATGAATTCCA G              51 
           
           
             
               41 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             71
CTGGAATTCA TGCATCTAGA GCGCTTTTCG GTTCAGCCGG T                         41 
           
           
             
               49 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             72
AAAGCTGCTA TCGCTCCGGC TAAAGCTGCT GCTGCTCCGG CTAAAGCTG                 49 
           
           
             
               39 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             73
CGGAGCAGCA GCAGCTTTAG CCGGAGCGAT AGCAGCTTT                            39 
           
           
             
               29 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             74
CTACCGCTCC GGCCGGCTCG AGATGCATG                                       29 
           
           
             
               43 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             75
AATTCATGCA TCTCGAGCCG GCCGGAGCGG TAGCAGCTTT AGC                       43 
           
           
             
               49 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             76
TCTTCTATGC CGTCTGGTAC CTCTGAAGAA GGTTCTCGTG GTGGTTCTT                 49 
           
           
             
               39 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             77
ACGAGAACCT TCTTCAGAGG TACCAGACGG CATAGAAGA                            39 
           
           
             
               26 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             78
CTATGCCGGC CGGCTCGAGA TGCATG                                          26 
           
           
             
               40 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             79
AATTCATGCA TCTCGAGCCG GCCGGCATAG AAGAACCACC                           40 
           
           
             
               23 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             80
ATACCCCGGG GACAACCGTC TCC                                             23 
           
           
             
               26 base pairs 
               nucleic acid 
               single 
               linear 
             
             
               DNA (genomic) 
             
             
               Trypanosoma cruzi 
             
             81
CGCCTTAGCC TGGAATTCAT GCATCT                                          26